{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:56:17Z","timestamp":1782489377351,"version":"3.54.5"},"reference-count":256,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Alzheimer\u2019s disease (AD) is one of the most prevalent neurodegenerative disorders. The pathological hallmarks of AD are amyloid-beta (A\u03b2) plaques and tau protein tangles, which cause neurodegeneration and lead to cognitive decline. The distinguished role of A\u03b2 plaques in the onset of the disease, especially in familial AD, alongside the genetic complexity of AD, underscores the need for precise and targeted genetic interventions targeting A\u03b2. This review first highlights the amyloidogenic and non-amyloidogenic pathways and inflammatory mechanisms contributing to A\u03b2 accumulation. It also introduces the role of genetic variants such as\n                    <jats:italic>amyloid precursor protein (APP), presenilin (PSEN1), PSEN2, and Apolipoprotein E (APOE)<\/jats:italic>\n                    alongside the molecular and cellular mechanisms involved in A\u03b2 pathology. Then, gene therapy techniques are discussed for their potential to target A\u03b2 either directly by inhibiting its production or enhancing its degradation or indirectly by targeting APOE, inflammatory pathways, and neurotrophic factors. While these approaches show significant preclinical promise, challenges such as timing, safety, and delivery across the blood\u2013brain barrier persist and need further investigation.\n                  <\/jats:p>","DOI":"10.1515\/revneuro-2025-0025","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:48:16Z","timestamp":1748652496000},"page":"825-848","source":"Crossref","is-referenced-by-count":1,"title":["From genetic roots to recent advancements in gene therapy targeting amyloid beta in Alzheimer\u2019s disease"],"prefix":"10.1515","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5052-2104","authenticated-orcid":false,"given":"Pinar","family":"Peyvand","sequence":"first","affiliation":[{"name":"Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN) , Children\u2019s Medical Center Hospital , Dr. Qarib St, Keshavarz Blvd , Tehran , 14194 , Iran"},{"name":"School of Medicine , 48439 Tehran University of Medical Sciences , Pour Sina St , Tehran , 1416634793 , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0311-6568","authenticated-orcid":false,"given":"Pantea","family":"Allami","sequence":"additional","affiliation":[{"name":"Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN) , Children\u2019s Medical Center Hospital , Dr. Qarib St, Keshavarz Blvd , Tehran , 14194 , Iran"},{"name":"School of Medicine , 48439 Tehran University of Medical Sciences , Pour Sina St , Tehran , 1416634793 , Iran"},{"name":"Students\u2019 Scientific Research Center , Tehran University of Medical Sciences , Italy St Cross, St, Vesal Shirazi , Tehran , 1417755331 , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[{"name":"Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN) , Children\u2019s Medical Center Hospital , Dr. Qarib St, Keshavarz Blvd , Tehran , 14194 , Iran"},{"name":"Research Center for Immunodeficiencies, Children\u2019s Medical Center , Tehran University of Medical Sciences , Dr. Qarib St, Keshavarz Blvd , Tehran , 14194 , Iran"},{"name":"Department of Immunology, School of Medicine , Tehran University of Medical Sciences , Dr. Qarib St, Keshavarz Blvd , Tehran , 14194 , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2026022416431476121_j_revneuro-2025-0025_ref_001","doi-asserted-by":"crossref","unstructured":"Al-Atrache, Z., Lopez, D.B., Hingley, S.T., and Appelt, D.M. (2019). Astrocytes infected with Chlamydia pneumoniae demonstrate altered expression and activity of secretases involved in the generation of \u03b2-amyloid found in Alzheimer disease. BMC Neurosci. 20: 6, https:\/\/doi.org\/10.1186\/s12868-019-0489-5.","DOI":"10.1186\/s12868-019-0489-5"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_002","doi-asserted-by":"crossref","unstructured":"Ali, N.H., Al-Kuraishy, H.M., Al-Gareeb, A.I., Alnaaim, S.A., Alexiou, A., Papadakis, M., Khalifa, A.A., Saad, H.M., and Batiha, G.E. (2024). Neprilysin inhibitors and risk of Alzheimer\u2019s disease: A future perspective. J.\u00a0Cell. Mol. Med. 28: e17993, https:\/\/doi.org\/10.1111\/jcmm.17993.","DOI":"10.1111\/jcmm.17993"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_261","unstructured":"Allen, S.J. and Dawbarn, D. (2009). Chapter 4: Pathophysiology of Alzheimer\u2019s disease. In: Waldemar, G. and Burns, A. (Eds.), Alzheimer\u2019s disease, 1st ed. Oxford University Press, Oxford, UK, pp. 27\u201335."},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_004","unstructured":"Alzheimer\u2019s disease international (2021). Dementia Stat., Available at:https:\/\/www.alzint.org\/about\/dementia-facts-figures\/dementia-statistics\/."},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_005","doi-asserted-by":"crossref","unstructured":"Amelimojarad, M., Amelimojarad, M., and Cui, X. (2024). The emerging role of brain neuroinflammatory responses in Alzheimer\u2019s disease. Front Aging Neurosci. 16: 1391517, https:\/\/doi.org\/10.3389\/fnagi.2024.1391517.","DOI":"10.3389\/fnagi.2024.1391517"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_006","doi-asserted-by":"crossref","unstructured":"Arora, S., Layek, B., and Singh, J. (2021). Design and validation of liposomal ApoE2 gene delivery system to evade blood-brain barrier for effective treatment of Alzheimer\u2019s disease. Mol. Pharm. 18: 714\u2013725, https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00461.","DOI":"10.1021\/acs.molpharmaceut.0c00461"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_007","doi-asserted-by":"crossref","unstructured":"Arora, S., Kanekiyo, T., and Singh, J. (2022). Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer\u2019s disease pathology in transgenic mouse model. Int. J.\u00a0Biol. Macromol. 208: 901\u2013911, https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.03.203.","DOI":"10.1016\/j.ijbiomac.2022.03.203"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_008","doi-asserted-by":"crossref","unstructured":"Ashrafian, H., Zadeh, E.H., and Khan, R.H. (2021). Review on Alzheimer\u2019s disease: inhibition of amyloid beta and tau tangle formation. Int. J.\u00a0Biol. Macromol. 167: 382\u2013394, https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.11.192.","DOI":"10.1016\/j.ijbiomac.2020.11.192"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_009","doi-asserted-by":"crossref","unstructured":"Ataei, B., Hokmabadi, M., Asadi, S., Asadifard, E., Aghaei Zarch, S.M., Najafi, S., and Bagheri-Mohammadi, S. (2024). A review of the advances, insights, and prospects of gene therapy for Alzheimer\u2019s disease: a novel target for therapeutic medicine. Gene 912: 148368, https:\/\/doi.org\/10.1016\/j.gene.2024.148368.","DOI":"10.1016\/j.gene.2024.148368"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_010","doi-asserted-by":"crossref","unstructured":"Atagi, Y., Liu, C.C., Painter, M.M., Chen, X.F., Verbeeck, C., Zheng, H., Li, X., Rademakers, R., Kang, S.S., Xu, H., et al.. (2015). Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J.\u00a0Biol. Chem. 290: 26043\u201326050, https:\/\/doi.org\/10.1074\/jbc.m115.679043.","DOI":"10.1074\/jbc.M115.679043"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_011","doi-asserted-by":"crossref","unstructured":"Bagaria, J., Bagyinszky, E., and An, S.S.A. (2022). Genetics, functions, and clinical impact of presenilin-1 (PSEN1) gene. Int. J.\u00a0Mol. Sci. 23, https:\/\/doi.org\/10.3390\/ijms231810970.","DOI":"10.3390\/ijms231810970"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_012","doi-asserted-by":"crossref","unstructured":"Ballinger, C.A., Connell, P., Wu, Y., Hu, Z., Thompson, L.J., Yin, L.Y., and Patterson, C. (1999). Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19: 4535\u20134545, https:\/\/doi.org\/10.1128\/mcb.19.6.4535.","DOI":"10.1128\/MCB.19.6.4535"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_013","doi-asserted-by":"crossref","unstructured":"Baranello, R.J., Bharani, K.L., Padmaraju, V., Chopra, N., Lahiri, D.K., Greig, N.H., Pappolla, M.A., and Sambamurti, K. (2015). Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer\u2019s disease. Curr. Alzheimer Res. 12: 32\u201346, https:\/\/doi.org\/10.2174\/1567205012666141218140953.","DOI":"10.2174\/1567205012666141218140953"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_014","doi-asserted-by":"crossref","unstructured":"Bekris, L.M., Yu, C.E., Bird, T.D., and Tsuang, D.W. (2010). Genetics of Alzheimer disease. J.\u00a0Geriatr. Psychiatry Neurol. 23: 213\u2013227, https:\/\/doi.org\/10.1177\/0891988710383571.","DOI":"10.1177\/0891988710383571"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_015","doi-asserted-by":"crossref","unstructured":"Benilova, I. and De Strooper, B. (2013). Neuroscience. Promiscuous Alzheimer\u2019s amyloid: yet another partner. Science 341: 1354\u20131355, https:\/\/doi.org\/10.1126\/science.1244166.","DOI":"10.1126\/science.1244166"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_016","doi-asserted-by":"crossref","unstructured":"Bergen, J.M., Park, I.K., Horner, P.J., and Pun, S.H. (2008). Nonviral approaches for neuronal delivery of nucleic acids. Pharm. Res. 25: 983\u2013998, https:\/\/doi.org\/10.1007\/s11095-007-9439-5.","DOI":"10.1007\/s11095-007-9439-5"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_017","doi-asserted-by":"crossref","unstructured":"Bradshaw, E.M., Chibnik, L.B., Keenan, B.T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L.L., Imboywa, S., Lee, M., Von Korff, A., et al.. (2013). CD33 Alzheimer\u2019s disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 16: 848\u2013850, https:\/\/doi.org\/10.1038\/nn.3435.","DOI":"10.1038\/nn.3435"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_018","doi-asserted-by":"crossref","unstructured":"Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer\u2019s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10: 333\u2013344, https:\/\/doi.org\/10.1038\/nrn2620.","DOI":"10.1038\/nrn2620"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_019","doi-asserted-by":"crossref","unstructured":"Busciglio, J., Gabuzda, D.H., Matsudaira, P., and Yankner, B.A. (1993). Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci USA 90: 2092\u20132096, https:\/\/doi.org\/10.1073\/pnas.90.5.2092.","DOI":"10.1073\/pnas.90.5.2092"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_020","doi-asserted-by":"crossref","unstructured":"Cacabelos, R. (2020). How plausible is an Alzheimer\u2019s disease vaccine? Expert Opin. Drug Discov. 15: 1\u20136, https:\/\/doi.org\/10.1080\/17460441.2019.1667329.","DOI":"10.1080\/17460441.2019.1667329"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_021","doi-asserted-by":"crossref","unstructured":"Cacace, R., Sleegers, K., and Van Broeckhoven, C. (2016). Molecular genetics of early-onset Alzheimer\u2019s disease revisited. Alzheimers Dement 12: 733\u2013748, https:\/\/doi.org\/10.1016\/j.jalz.2016.01.012.","DOI":"10.1016\/j.jalz.2016.01.012"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_022","doi-asserted-by":"crossref","unstructured":"Cai, Y., An, S.S., and Kim, S. (2015). Mutations in presenilin 2 and its implications in Alzheimer\u2019s disease and other dementia-associated disorders. Clin. Interv. Aging. 10: 1163\u20131172, https:\/\/doi.org\/10.2147\/cia.s85808.","DOI":"10.2147\/CIA.S85808"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_023","doi-asserted-by":"crossref","unstructured":"Carty, N., Nash, K.R., Brownlow, M., Cruite, D., Wilcock, D., Selenica, M.L., Lee, D.C., Gordon, M.N., and Morgan, D. (2013). Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PLoS One 8: e59626, https:\/\/doi.org\/10.1371\/journal.pone.0059626.","DOI":"10.1371\/journal.pone.0059626"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_024","doi-asserted-by":"crossref","unstructured":"Chanana, N. and Pati, U. (2018). ORP150-CHIP chaperone antagonism control BACE1-mediated amyloid processing. J.\u00a0Cell. Biochem. 119: 4615\u20134626, https:\/\/doi.org\/10.1002\/jcb.26630.","DOI":"10.1002\/jcb.26630"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_025","doi-asserted-by":"crossref","unstructured":"Chang, J.L., Hinrich, A.J., Roman, B., Norrbom, M., Rigo, F., Marr, R.A., Norstrom, E.M., and Hastings, M.L. (2018). Targeting amyloid-\u03b2 precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-\u03b2 production. Mol. Ther. 26: 1539\u20131551, https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.029.","DOI":"10.1016\/j.ymthe.2018.02.029"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_026","doi-asserted-by":"crossref","unstructured":"Chen, X., Hu, Y., Cao, Z., Liu, Q., and Cheng, Y. (2018). Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer\u2019s disease, Parkinson\u2019s disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Immunol. 9: 2122, https:\/\/doi.org\/10.3389\/fimmu.2018.02122.","DOI":"10.3389\/fimmu.2018.02122"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_027","doi-asserted-by":"crossref","unstructured":"Chen, W., Hu, Y., and Ju, D. (2020). Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm. Sin. B 10: 1347\u20131359, https:\/\/doi.org\/10.1016\/j.apsb.2020.01.015.","DOI":"10.1016\/j.apsb.2020.01.015"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_028","doi-asserted-by":"crossref","unstructured":"Cheng, S., Tereshchenko, J., Zimmer, V., Vachey, G., Pythoud, C., Rey, M., Liefhebber, J., Raina, A., Streit, F., Mazur, A., et al.. (2018). Therapeutic efficacy of regulable GDNF expression for Huntington\u2019s and Parkinson\u2019s disease by a high-induction, background-free \u201cGeneSwitch\u201d vector. Exp. Neurol. 309: 79\u201390, https:\/\/doi.org\/10.1016\/j.expneurol.2018.07.017.","DOI":"10.1016\/j.expneurol.2018.07.017"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_029","doi-asserted-by":"crossref","unstructured":"Ciss\u00e9, M., Duplan, E., Lorivel, T., Dunys, J., Bauer, C., Meckler, X., Gerakis, Y., Lauritzen, I., and Checler, F. (2017). The transcription factor XBP1s restores hippocampal synaptic plasticity and memory by control of the Kalirin-7 pathway in Alzheimer model. Mol. Psychiatry 22: 1562\u20131575, https:\/\/doi.org\/10.1038\/mp.2016.152.","DOI":"10.1038\/mp.2016.152"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_030","doi-asserted-by":"crossref","unstructured":"Citron, M., Vigo-Pelfrey, C., Teplow, D.B., Miller, C., Schenk, D., Johnston, J., Winblad, B., Venizelos, N., Lannfelt, L., and Selkoe, D.J. (1994). Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc. Natl Acad Sci USA 91: 11993\u201311997, https:\/\/doi.org\/10.1073\/pnas.91.25.11993.","DOI":"10.1073\/pnas.91.25.11993"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_031","doi-asserted-by":"crossref","unstructured":"Cochran, J.N., Rush, T., Buckingham, S.C., and Roberson, E.D. (2015). The Alzheimer\u2019s disease risk factor CD2AP maintains blood-brain barrier integrity. Hum. Mol. Genet. 24: 6667\u20136674, https:\/\/doi.org\/10.1093\/hmg\/ddv371.","DOI":"10.1093\/hmg\/ddv371"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_032","doi-asserted-by":"crossref","unstructured":"Colucci-D\u2019Amato, L., Speranza, L., and Volpicelli, F. (2020). Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int. J.\u00a0Mol. Sci. 21, https:\/\/doi.org\/10.3390\/ijms21207777.","DOI":"10.3390\/ijms21207777"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_033","unstructured":"Cozaru, G.C., A\u015fchie, M., Mitroi, A.F., Poin\u0103reanu, I., and Gorduza, E.V. (2016). Ethical and genetic aspects regarding presymptomatic testing for neurodegenerative diseases. Rev. Med. Chir. Soc. Med. Nat. Iasi 120: 15\u201322."},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_034","doi-asserted-by":"crossref","unstructured":"Crouch, P.J., Blake, R., Duce, J.A., Ciccotosto, G.D., Li, Q.X., Barnham, K.J., Curtain, C.C., Cherny, R.A., Cappai, R., Dyrks, T., et al.. (2005). Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J.\u00a0Neurosci. 25: 672\u2013679, https:\/\/doi.org\/10.1523\/jneurosci.4276-04.2005.","DOI":"10.1523\/JNEUROSCI.4276-04.2005"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_035","doi-asserted-by":"crossref","unstructured":"Cummings, J., Ritter, A., and Zhong, K. (2018). Clinical trials for disease-modifying therapies in Alzheimer\u2019s disease: a primer, lessons learned, and a blueprint for the future. J.\u00a0Alzheimers Dis. 64: S3\u2013s22, https:\/\/doi.org\/10.3233\/jad-179901.","DOI":"10.3233\/JAD-179901"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_036","doi-asserted-by":"crossref","unstructured":"Cummins, T.D., Wu, K.Z.L., Bozatzi, P., Dingwell, K.S., Macartney, T.J., Wood, N.T., Varghese, J., Gourlay, R., Campbell, D.G., Prescott, A., et al.. (2018). PAWS1 controls cytoskeletal dynamics and cell migration through association with the SH3 adaptor CD2AP. J.\u00a0Cell Sci. 131, https:\/\/doi.org\/10.1242\/jcs.202390.","DOI":"10.1242\/jcs.202390"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_037","doi-asserted-by":"crossref","unstructured":"Dobson, J. (2006). Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 13: 283\u2013287, https:\/\/doi.org\/10.1038\/sj.gt.3302720.","DOI":"10.1038\/sj.gt.3302720"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_038","doi-asserted-by":"crossref","unstructured":"Doody, R.S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R.G., et al.. (2013). A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N.\u00a0Engl. J.\u00a0Med. 369: 341\u2013350, https:\/\/doi.org\/10.1056\/nejmoa1210951.","DOI":"10.1056\/NEJMoa1210951"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_039","doi-asserted-by":"crossref","unstructured":"Doshi, V., Joshi, G., Sharma, S., and Choudhary, D. (2024). Gene therapy: an alternative to treat Alzheimer\u2019s disease. Naunyn. Schmiedebergs Arch. Pharmacol. 397: 3675\u20133693, https:\/\/doi.org\/10.1007\/s00210-023-02873-z.","DOI":"10.1007\/s00210-023-02873-z"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_040","doi-asserted-by":"crossref","unstructured":"Dourlen, P., Kilinc, D., Malmanche, N., Chapuis, J., and Lambert, J.C. (2019). The new genetic landscape of Alzheimer\u2019s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol. 138: 221\u2013236, https:\/\/doi.org\/10.1007\/s00401-019-02004-0.","DOI":"10.1007\/s00401-019-02004-0"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_041","doi-asserted-by":"crossref","unstructured":"Dropuli\u0107, B., H\u0115rm\u00e1nkov\u00e1, M., and Pitha, P.M. (1996). A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc. Natl. Acad. Sci. U. S. A. 93: 11103\u201311108, https:\/\/doi.org\/10.1073\/pnas.93.20.11103.","DOI":"10.1073\/pnas.93.20.11103"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_042","doi-asserted-by":"crossref","unstructured":"Duan, Y., Ye, T., Qu, Z., Chen, Y., Miranda, A., Zhou, X., Lok, K.C., Chen, Y., Fu, A.K.Y., Gradinaru, V., et al.. (2022). Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer\u2019s disease alleviates amyloid-related pathologies in mice. Nat. Biomed. Eng. 6: 168\u2013180, https:\/\/doi.org\/10.1038\/s41551-021-00759-0.","DOI":"10.1038\/s41551-021-00759-0"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_043","doi-asserted-by":"crossref","unstructured":"Duran-Aniotz, C., Poblete, N., Rivera-Krstulovic, C., Ardiles \u00c1, O., D\u00edaz-Hung, M.L., Tamburini, G., Sabusap, C.M.P., Gerakis, Y., Cabral-Miranda, F., Diaz, J., et al.. (2023). The unfolded protein response transcription factor XBP1s ameliorates Alzheimer\u2019s disease by improving synaptic function and proteostasis. Mol. Ther. 31: 2240\u20132256, https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.028.","DOI":"10.1016\/j.ymthe.2023.03.028"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_044","doi-asserted-by":"crossref","unstructured":"Dykens, J.A. (1994). Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated CA2+ and Na+: implications for neurodegeneration. J.\u00a0Neurochem. 63: 584\u2013591, https:\/\/doi.org\/10.1046\/j.1471-4159.1994.63020584.x.","DOI":"10.1046\/j.1471-4159.1994.63020584.x"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_045","doi-asserted-by":"crossref","unstructured":"Eckert, A., Schulz, K.L., Rhein, V., and G\u00f6tz, J. (2010). Convergence of amyloid-beta and tau pathologies on mitochondria in\u00a0vivo. Mol. Neurobiol. 41: 107\u2013114, https:\/\/doi.org\/10.1007\/s12035-010-8109-5.","DOI":"10.1007\/s12035-010-8109-5"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_046","doi-asserted-by":"crossref","unstructured":"Escartin, C., Galea, E., Lakatos, A., O\u2019Callaghan, J.P., Petzold, G.C., Serrano-Pozo, A., Steinh\u00e4user, C., Volterra, A., Carmignoto, G., Agarwal, A., et al.. (2021). Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 24: 312\u2013325, https:\/\/doi.org\/10.1038\/s41593-020-00783-4.","DOI":"10.1038\/s41593-020-00783-4"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_047","doi-asserted-by":"crossref","unstructured":"Faingold, C.L. (2014). Chapter 7 \u2013 network control mechanisms: cellular inputs, neuroactive substances, and synaptic changes. In: Faingold, C.L. and Blumenfeld, H. (Eds.). Neuronal Networks in brain function, CNS disorders, and therapeutics. Academic Press, San Diego, pp. 91\u2013101.","DOI":"10.1016\/B978-0-12-415804-7.00007-1"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_048","doi-asserted-by":"crossref","unstructured":"Falkevall, A., Alikhani, N., Bhushan, S., Pavlov, P.F., Busch, K., Johnson, K.A., Eneqvist, T., Tjernberg, L., Ankarcrona, M., and Glaser, E. (2006). Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP. J.\u00a0Biol. Chem. 281: 29096\u201329104, https:\/\/doi.org\/10.1074\/jbc.m602532200.","DOI":"10.1074\/jbc.M602532200"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_049","doi-asserted-by":"crossref","unstructured":"Fan, Z., Brooks, D.J., Okello, A., and Edison, P. (2017). An early and late peak in microglial activation in Alzheimer\u2019s disease trajectory. Brain 140: 792\u2013803, https:\/\/doi.org\/10.1093\/brain\/aww349.","DOI":"10.1093\/brain\/aww349"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_050","doi-asserted-by":"crossref","unstructured":"Fan, F., Liu, H., Shi, X., Ai, Y., Liu, Q., and Cheng, Y. (2022). The efficacy and safety of Alzheimer\u2019s disease therapies: an updated umbrella review. J.\u00a0Alzheimers Dis. 85: 1195\u20131204, https:\/\/doi.org\/10.3233\/jad-215423.","DOI":"10.3233\/JAD-215423"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_051","doi-asserted-by":"crossref","unstructured":"Fan, F.C., Liu, L.M., Guo, M., Du, Y., Chen, Y.W., Loh, Y.P., and Cheng, Y. (2025). Neurotrophic factor-\u03b11\/carboxypeptidase E controls progression and reversal of Alzheimer\u2019s disease pathogenesis in mice. Theranostics 15: 2279\u20132292, https:\/\/doi.org\/10.7150\/thno.99908.","DOI":"10.7150\/thno.99908"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_052","doi-asserted-by":"crossref","unstructured":"Fargali, S., Sadahiro, M., Jiang, C., Frick, A.L., Indall, T., Cogliani, V., Welagen, J., Lin, W.J., and Salton, S.R. (2012). Role of neurotrophins in the development and function of neural circuits that regulate energy homeostasis. J.\u00a0Mol. Neurosci. 48: 654\u2013659, https:\/\/doi.org\/10.1007\/s12031-012-9790-9.","DOI":"10.1007\/s12031-012-9790-9"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_053","doi-asserted-by":"crossref","unstructured":"Feldman, H.H. and Lane, R. (2007). Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer\u2019s disease. J.\u00a0Neurol. Neurosurg. Psychiatry 78: 1056\u20131063, https:\/\/doi.org\/10.1136\/jnnp.2006.099424.","DOI":"10.1136\/jnnp.2006.099424"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_054","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Morales, J.C., Arranz-Tagarro, J.A., Calvo-Gallardo, E., Maroto, M., Pad\u00edn, J.F., and Garc\u00eda, A.G. (2012). Stabilizers of neuronal and mitochondrial calcium cycling as a strategy for developing a medicine for Alzheimer\u2019s disease. ACS Chem. Neurosci. 3: 873\u2013883, https:\/\/doi.org\/10.1021\/cn3001069.","DOI":"10.1021\/cn3001069"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_055","doi-asserted-by":"crossref","unstructured":"Fi\u0161ar, Z. (2022). Linking the amyloid, tau, and mitochondrial hypotheses of Alzheimer\u2019s disease and identifying promising drug targets. Biomolecules. 12, https:\/\/doi.org\/10.3390\/biom12111676.","DOI":"10.3390\/biom12111676"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_056","doi-asserted-by":"crossref","unstructured":"Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedr\u00f3s, I., Marin, M., Olloquequi, J., and Camins, A. (2018). Review of the advances in treatment for Alzheimer disease: strategies for combating \u03b2-amyloid protein. Neurologia (Engl Ed). 33: 47\u201358, https:\/\/doi.org\/10.1016\/j.nrleng.2015.03.019.","DOI":"10.1016\/j.nrleng.2015.03.019"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_057","doi-asserted-by":"crossref","unstructured":"Francis, P.T., Palmer, A.M., Snape, M. and Wilcock, G.K. (1999). The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress. J.\u00a0Neurol. Neurosurg. Psychiatr. 66: 137, https:\/\/doi.org\/10.1136\/jnnp.66.2.137.","DOI":"10.1136\/jnnp.66.2.137"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_058","doi-asserted-by":"crossref","unstructured":"Frost, G.R. and Li, Y.M. (2017). The role of astrocytes in amyloid production and Alzheimer\u2019s disease. Open Biol. 7, https:\/\/doi.org\/10.1098\/rsob.170228.","DOI":"10.1098\/rsob.170228"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_059","doi-asserted-by":"crossref","unstructured":"Gao, L., Zhang, Y., Sterling, K., and Song, W. (2022). Brain-derived neurotrophic factor in Alzheimer\u2019s disease and its pharmaceutical potential. Transl. Neurodegener. 11: 4, https:\/\/doi.org\/10.1186\/s40035-022-00279-0.","DOI":"10.1186\/s40035-022-00279-0"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_265","unstructured":"Gerakis, Y. (2016). Stress r\u00e9ticulaire et maladie d\u2019Alzheimer: contribution du facteur de transcription XBP-1s, Doctoral dissertation. Nice, France, COMUE Universit\u00e9 C\u00f4te d\u2019Azur."},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_062","doi-asserted-by":"crossref","unstructured":"Gomazkov, O.A. (2012). Neurotrophins: the therapeutic potential and concept of minipeptides. Neurochem. J. 6: 163\u2013172, https:\/\/doi.org\/10.1134\/s1819712412030075.","DOI":"10.1134\/S1819712412030075"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_063","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Reyes, R.E., Nava-Mesa, M.O., Vargas-S\u00e1nchez, K., Ariza-Salamanca, D., and Mora-Mu\u00f1oz, L. (2017). Involvement of astrocytes in Alzheimer\u2019s disease from a neuroinflammatory and oxidative stress perspective. Front Mol. Neurosci. 10: 427, https:\/\/doi.org\/10.3389\/fnmol.2017.00427.","DOI":"10.3389\/fnmol.2017.00427"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_064","doi-asserted-by":"crossref","unstructured":"Goodwin, J.L., Uemura, E., and Cunnick, J.E. (1995). Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. Brain Res. 692: 207\u2013214, https:\/\/doi.org\/10.1016\/0006-8993(95)00646-8.","DOI":"10.1016\/0006-8993(95)00646-8"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_065","doi-asserted-by":"crossref","unstructured":"Griciuc, A., Federico, A.N., Natasan, J., Forte, A.M., McGinty, D., Nguyen, H., Volak, A., LeRoy, S., Gandhi, S., Lerner, E.P., et al.. (2020). Gene therapy for Alzheimer\u2019s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum. Mol. Genet. 29: 2920\u20132935, https:\/\/doi.org\/10.1093\/hmg\/ddaa179.","DOI":"10.1093\/hmg\/ddaa179"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_066","doi-asserted-by":"crossref","unstructured":"Gu, L. and Guo, Z. (2013). Alzheimer\u2019s A\u03b242 and A\u03b240 peptides form interlaced amyloid fibrils. J.\u00a0Neurochem. 126: 305\u2013311, https:\/\/doi.org\/10.1111\/jnc.12202.","DOI":"10.1111\/jnc.12202"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_067","doi-asserted-by":"crossref","unstructured":"Guan, H., Liu, Y., Daily, A., Police, S., Kim, M.H., Oddo, S., LaFerla, F.M., Pauly, J.R., Murphy, M.P., and Hersh, L.B. (2009). Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer\u2019s disease. J.\u00a0Neurosci. Res. 87: 1462\u20131473, https:\/\/doi.org\/10.1002\/jnr.21944.","DOI":"10.1002\/jnr.21944"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_068","doi-asserted-by":"crossref","unstructured":"Gulisano, W., Maugeri, D., Baltrons, M.A., F\u00e0, M., Amato, A., Palmeri, A., D\u2019Adamio, L., Grassi, C., Devanand, D.P., Honig, L.S., et al.. (2018). Role of amyloid-\u03b2 and tau proteins in Alzheimer\u2019s disease: confuting the amyloid cascade. J.\u00a0Alzheimers Dis. 64: S611\u2013s631, https:\/\/doi.org\/10.3233\/jad-179935.","DOI":"10.3233\/JAD-179935"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_069","doi-asserted-by":"crossref","unstructured":"Gustavsson, A., Norton, N., Fast, T., Fr\u00f6lich, L., Georges, J., Holzapfel, D., Kirabali, T., Krolak-Salmon, P., Rossini, P.M., Ferretti, M.T., et al.. (2023). Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement 19: 658\u2013670, https:\/\/doi.org\/10.1002\/alz.12694.","DOI":"10.1002\/alz.12694"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_070","doi-asserted-by":"crossref","unstructured":"Habib, N., McCabe, C., Medina, S., Varshavsky, M., Kitsberg, D., Dvir-Szternfeld, R., Green, G., Dionne, D., Nguyen, L., Marshall, J.L., et al.. (2020). Disease-associated astrocytes in Alzheimer\u2019s disease and aging. Nat. Neurosci. 23: 701\u2013706, https:\/\/doi.org\/10.1038\/s41593-020-0624-8.","DOI":"10.1038\/s41593-020-0624-8"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_071","doi-asserted-by":"crossref","unstructured":"Hampel, H., Mesulam, M.M., Cuello, A.C., Farlow, M.R., Giacobini, E., Grossberg, G.T., Khachaturian, A.S., Vergallo, A., Cavedo, E., Snyder, P.J., et al.. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 141: 1917\u20131933, https:\/\/doi.org\/10.1093\/brain\/awy132.","DOI":"10.1093\/brain\/awy132"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_072","doi-asserted-by":"crossref","unstructured":"Hampel, H., Mesulam, M.M., Cuello, A.C., Khachaturian, A.S., Vergallo, A., Farlow, M.R., Snyder, P.J., Giacobini, E., and Khachaturian, Z.S. (2019). Revisiting the cholinergic hypothesis in Alzheimer\u2019s disease: emerging evidence from translational and clinical research. J.\u00a0Prev. Alzheimers Dis. 6: 2\u201315, https:\/\/doi.org\/10.14283\/jpad.2018.43.","DOI":"10.14283\/jpad.2018.43"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_073","doi-asserted-by":"crossref","unstructured":"Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S.H., Villemagne, V.L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al.. (2021). The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mo.l Psychiatry 26: 5481\u20135503, https:\/\/doi.org\/10.1038\/s41380-021-01249-0.","DOI":"10.1038\/s41380-021-01249-0"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_074","doi-asserted-by":"crossref","unstructured":"Han, X., Zhang, T., Liu, H., Mi, Y., and Gou, X. (2020). Astrocyte senescence and Alzheimer\u2019s disease: a review. Front Aging Neurosci. 12: 148, https:\/\/doi.org\/10.3389\/fnagi.2020.00148.","DOI":"10.3389\/fnagi.2020.00148"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_075","doi-asserted-by":"crossref","unstructured":"Hao, W., Lenhart, S., and Petrella, J.R. (2022). Optimal anti-amyloid-beta therapy for Alzheimer\u2019s disease via a personalized mathematical model. PLoS Comput. Biol. 18: e1010481, https:\/\/doi.org\/10.1371\/journal.pcbi.1010481.","DOI":"10.1371\/journal.pcbi.1010481"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_076","doi-asserted-by":"crossref","unstructured":"He, K., Nie, L., Ali, T., Wang, S., Chen, X., Liu, Z., Li, W., Zhang, K., Xu, J., Liu, J., et al.. (2021). Adiponectin alleviated Alzheimer-like pathologies via autophagy-lysosomal activation. Aging Cell 20: e13514, https:\/\/doi.org\/10.1111\/acel.13514.","DOI":"10.1111\/acel.13514"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_077","unstructured":"Holland, K.L., C. (2023). Life expectancy and long-term outlook for Alzheimer\u2019s disease, Available at:https:\/\/www.healthline.com\/health\/alzheimers\/life-expectancy#fa-qs."},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_078","doi-asserted-by":"crossref","unstructured":"Holtzman, D.M., Fagan, A.M., Mackey, B., Tenkova, T., Sartorius, L., Paul, S.M., Bales, K., Ashe, K.H., Irizarry, M.C., and Hyman, B.T. (2000). Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer\u2019s disease model. Ann Neurol. 47: 739\u2013747, https:\/\/doi.org\/10.1002\/1531-8249(200006)47:6<739::aid-ana6>3.3.co;2-#.","DOI":"10.1002\/1531-8249(200006)47:6<739::AID-ANA6>3.3.CO;2-#"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_079","doi-asserted-by":"crossref","unstructured":"Hu, Z., Yang, J., Zhang, S., Li, M., Zuo, C., Mao, C., Zhang, Z., Tang, M., Shi, C., and Xu, Y. (2025). AAV mediated carboxyl terminus of Hsp70 interacting protein overexpression mitigates the cognitive and pathological phenotypes of APP\/PS1 mice. Neural Regen Res. 20: 253\u2013264, https:\/\/doi.org\/10.4103\/nrr.nrr-d-23-01277.","DOI":"10.4103\/NRR.NRR-D-23-01277"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_080","doi-asserted-by":"crossref","unstructured":"Huang, Y. and Mahley, R.W. (2014). Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer\u2019s diseases. Neurobiol. Dis. 72: 3\u201312, https:\/\/doi.org\/10.1016\/j.nbd.2014.08.025.","DOI":"10.1016\/j.nbd.2014.08.025"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_081","doi-asserted-by":"crossref","unstructured":"Huang, Z., Ha, G., and Petitto, J. (2014). Reversal of neuronal atrophy: role of cellular immunity in neuroplasticity and aging. J.\u00a0Neurol. Disord. 2, https:\/\/doi.org\/10.4172\/2329-6895.1000170.","DOI":"10.4172\/2329-6895.1000170"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_082","doi-asserted-by":"crossref","unstructured":"Huang, S., Liao, X., Wu, J., Zhang, X., Li, Y., Xiang, D., and Luo, S. (2022). The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid-\u03b2 by microglia. FEBS Lett. 596: 1059\u20131071, https:\/\/doi.org\/10.1002\/1873-3468.14336.","DOI":"10.1002\/1873-3468.14336"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_083","doi-asserted-by":"crossref","unstructured":"Husna Ibrahim, N., Yahaya, M.F., Mohamed, W., Teoh, S.L., Hui, C.K., and Kumar, J. (2020). Pharmacotherapy of Alzheimer\u2019s disease: seeking clarity in a time of uncertainty. Front. Pharmacol 11: 261, https:\/\/doi.org\/10.3389\/fphar.2020.00261.","DOI":"10.3389\/fphar.2020.00261"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_084","doi-asserted-by":"crossref","unstructured":"Imbimbo, B.P. and Watling, M. (2019). Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin. Investig. Drugs 28: 967\u2013975, https:\/\/doi.org\/10.1080\/13543784.2019.1683160.","DOI":"10.1080\/13543784.2019.1683160"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_085","doi-asserted-by":"crossref","unstructured":"Iwata, N., Sekiguchi, M., Hattori, Y., Takahashi, A., Asai, M., Ji, B., Higuchi, M., Staufenbiel, M., Muramatsu, S., and Saido, T.C. (2013). Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci. Rep. 3: 1472, https:\/\/doi.org\/10.1038\/srep01472.","DOI":"10.1038\/srep01472"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_086","doi-asserted-by":"crossref","unstructured":"Jackson, R.J., Keiser, M.S., Meltzer, J.C., Fykstra, D.P., Dierksmeier, S.E., Hajizadeh, S., Kreuzer, J., Morris, R., Melloni, A., Nakajima, T., et al.. (2024). APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease. Mol. Ther. 32: 1373\u20131386, https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.024.","DOI":"10.1016\/j.ymthe.2024.03.024"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_087","doi-asserted-by":"crossref","unstructured":"Jandus, C., Simon, H.U., and von Gunten, S. (2011). Targeting siglecs--a novel pharmacological strategy for immuno- and glycotherapy. Biochem. Pharmacol. 82: 323\u2013332, https:\/\/doi.org\/10.1016\/j.bcp.2011.05.018.","DOI":"10.1016\/j.bcp.2011.05.018"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_088","doi-asserted-by":"crossref","unstructured":"Jang, H., Zheng, J., and Nussinov, R. (2007). Models of beta-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process. Biophys. J. 93: 1938\u20131949, https:\/\/doi.org\/10.1529\/biophysj.107.110148.","DOI":"10.1529\/biophysj.107.110148"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_089","doi-asserted-by":"crossref","unstructured":"Jayant, R.D., Sosa, D., Kaushik, A., Atluri, V., Vashist, A., Tomitaka, A., and Nair, M. (2016). Current status of non-viral gene therapy for CNS disorders. Expert Opin. Drug Deliv. 13: 1433\u20131445, https:\/\/doi.org\/10.1080\/17425247.2016.1188802.","DOI":"10.1080\/17425247.2016.1188802"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_090","doi-asserted-by":"crossref","unstructured":"Jeon, S.G., Yoo, A., Chun, D.W., Hong, S.B., Chung, H., Kim, J.I., and Moon, M. (2020). The critical role of Nurr1 as a mediator and therapeutic target in Alzheimer\u2019s disease-related pathogenesis. Aging Dis. 11: 705\u2013724, https:\/\/doi.org\/10.14336\/ad.2019.0718.","DOI":"10.14336\/AD.2019.0718"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_091","doi-asserted-by":"crossref","unstructured":"Jiang, S., Cai, G., Yang, Z., Shi, H., Zeng, H., Ye, Q., Hu, Z., and Wang, Z. (2024). Biomimetic nanovesicles as a dual gene delivery system for the synergistic gene therapy of Alzheimer\u2019s disease. ACS Nano 18: 11753\u201311768, https:\/\/doi.org\/10.1021\/acsnano.3c13150.","DOI":"10.1021\/acsnano.3c13150"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_092","doi-asserted-by":"crossref","unstructured":"Jiao, F., Jiang, D., Li, Y., Mei, J., Wang, Q., and Li, X. (2022). Amyloidogenesis and neurotrophic dysfunction in Alzheimer\u2019s disease: do they have a common regulating pathway? Cells 11, https:\/\/doi.org\/10.3390\/cells11203201.","DOI":"10.3390\/cells11203201"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_094","doi-asserted-by":"crossref","unstructured":"Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A.I., Lah, J.J., et al.. (2013). Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N.\u00a0Engl. J.\u00a0Med. 368: 107\u2013116, https:\/\/doi.org\/10.1056\/nejmoa1211103.","DOI":"10.1056\/NEJMoa1211103"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_095","doi-asserted-by":"crossref","unstructured":"Kabir, M.T., Uddin, M.S., Setu, J.R., Ashraf, G.M., Bin-Jumah, M.N., and Abdel-Daim, M.M. (2020). Exploring the role of PSEN mutations in the pathogenesis of Alzheimer\u2019s disease. Neurotox Res. 38: 833\u2013849, https:\/\/doi.org\/10.1007\/s12640-020-00232-x.","DOI":"10.1007\/s12640-020-00232-x"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_096","doi-asserted-by":"crossref","unstructured":"Kelleher, R.J.3rd and Shen, J. (2017). Presenilin-1 mutations and Alzheimer\u2019s disease. Proc. Natl. Acad. Sci. U. S. A. 114: 629\u2013631, https:\/\/doi.org\/10.1073\/pnas.1619574114.","DOI":"10.1073\/pnas.1619574114"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_097","doi-asserted-by":"crossref","unstructured":"Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T.K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al.. (2017). A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169: 1276\u20131290.e1217, https:\/\/doi.org\/10.1016\/j.cell.2017.05.018.","DOI":"10.1016\/j.cell.2017.05.018"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_098","doi-asserted-by":"crossref","unstructured":"Khakh, B.S. and Deneen, B. (2019). The emerging nature of astrocyte diversity. Annu. Rev. Neurosci. 42: 187\u2013207, https:\/\/doi.org\/10.1146\/annurev-neuro-070918-050443.","DOI":"10.1146\/annurev-neuro-070918-050443"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_099","doi-asserted-by":"crossref","unstructured":"Khalil, Y.A., Rab\u00e8s, J.-P., Boileau, C., and Varret, M. (2021). APOE gene variants in primary dyslipidemia. Atherosclerosis 328: 11\u201322, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.007.","DOI":"10.1016\/j.atherosclerosis.2021.05.007"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_100","doi-asserted-by":"crossref","unstructured":"Kieu, C. and Look, K.A. (2023). Cost-effectiveness of a hypothetical gene therapy for Alzheimer\u2019s disease: a markov simulation analysis. Innov Pharm. 14, https:\/\/doi.org\/10.24926\/iip.v14i3.5500.","DOI":"10.24926\/iip.v14i3.5500"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_101","doi-asserted-by":"crossref","unstructured":"Kim, M., Suh, J., Romano, D., Truong, M.H., Mullin, K., Hooli, B., Norton, D., Tesco, G., Elliott, K., Wagner, S.L., et al.. (2009). Potential late-onset Alzheimer\u2019s disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum. Mol. Genet. 18: 3987\u20133996, https:\/\/doi.org\/10.1093\/hmg\/ddp323.","DOI":"10.1093\/hmg\/ddp323"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_102","doi-asserted-by":"crossref","unstructured":"Kinney, J.W., Bemiller, S.M., Murtishaw, A.S., Leisgang, A.M., Salazar, A.M., and Lamb, B.T. (2018). Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y). 4: 575\u2013590, https:\/\/doi.org\/10.1016\/j.trci.2018.06.014.","DOI":"10.1016\/j.trci.2018.06.014"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_103","doi-asserted-by":"crossref","unstructured":"Kins, S., Lauther, N., Szodorai, A., and Beyreuther, K. (2006). Subcellular trafficking of the amyloid precursor protein gene family and its pathogenic role in Alzheimer\u2019s disease. Neurodegener Dis. 3: 218\u2013226, https:\/\/doi.org\/10.1159\/000095259.","DOI":"10.1159\/000095259"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_104","doi-asserted-by":"crossref","unstructured":"Kloske, C.M., Gearon, M.D., Weekman, E.M., Rogers, C., Patel, E., Bachstetter, A., Nelson, P.T., and Wilcock, D.M. (2023). Association between APOE genotype and microglial cell morphology. J.\u00a0Neuropathol. Exp. Neurol. 82: 620\u2013630, https:\/\/doi.org\/10.1093\/jnen\/nlad031.","DOI":"10.1093\/jnen\/nlad031"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_105","doi-asserted-by":"crossref","unstructured":"Knopman, D.S., Amieva, H., Petersen, R.C., Ch\u00e9telat, G., Holtzman, D.M., Hyman, B.T., Nixon, R.A., and Jones, D.T. (2021). Alzheimer disease. Nat. Rev. Dis. Primers 7: 33, https:\/\/doi.org\/10.1038\/s41572-021-00269-y.","DOI":"10.1038\/s41572-021-00269-y"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_106","doi-asserted-by":"crossref","unstructured":"Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D.Y., Petri, K., Aryee, M.J., Aguilar, X., Gy\u00f6rgy, B., et al.. (2022). CRISPR-Cas9 treatment partially restores amyloid-\u03b2 42\/40 in human fibroblasts with the Alzheimer\u2019s disease PSEN 1 M146L mutation. Mol. Ther. Nucleic Acids 28: 450\u2013461, https:\/\/doi.org\/10.1016\/j.omtn.2022.03.022.","DOI":"10.1016\/j.omtn.2022.03.022"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_107","doi-asserted-by":"crossref","unstructured":"Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O\u2019Loughlin, E., Xu, Y., Fanek, Z., et al.. (2017). The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47: 566\u2013581.e569, https:\/\/doi.org\/10.1016\/j.immuni.2017.08.008.","DOI":"10.1016\/j.immuni.2017.08.008"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_108","doi-asserted-by":"crossref","unstructured":"Kullmann, D.M. and Lamsa, K.P. (2007). Long-term synaptic plasticity in hippocampal interneurons. Nat. Rev. Neurosci. 8: 687\u2013699, https:\/\/doi.org\/10.1038\/nrn2207.","DOI":"10.1038\/nrn2207"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_109","doi-asserted-by":"crossref","unstructured":"Kumar, S.R., Markusic, D.M., Biswas, M., High, K.A., and Herzog, R.W. (2016). Clinical development of gene therapy: results and lessons from recent successes. Mol. Ther. Methods Clin. Dev. 3: 16034, https:\/\/doi.org\/10.1038\/mtm.2016.34.","DOI":"10.1038\/mtm.2016.34"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_110","unstructured":"Kumar, A., Sidhu, J., Lui, F., and Tsao, J.W. (2024). Alzheimer disease. StatPearls, Treasure Island (FL)."},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_111","doi-asserted-by":"crossref","unstructured":"Kummer, M.P., Hermes, M., Delekarte, A., Hammerschmidt, T., Kumar, S., Terwel, D., Walter, J., Pape, H.C., K\u00f6nig, S., Roeber, S., et al.. (2011). Nitration of tyrosine 10 critically enhances amyloid \u03b2 aggregation and plaque formation. Neuron 71: 833\u2013844, https:\/\/doi.org\/10.1016\/j.neuron.2011.07.001.","DOI":"10.1016\/j.neuron.2011.07.001"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_112","doi-asserted-by":"crossref","unstructured":"Kuszczyk, M.A., Sanchez, S., Pankiewicz, J., Kim, J., Duszczyk, M., Guridi, M., Asuni, A.A., Sullivan, P.M., Holtzman, D.M., and Sadowski, M.J. (2013). Blocking the interaction between apolipoprotein E and A\u03b2 reduces intraneuronal accumulation of A\u03b2 and inhibits synaptic degeneration. Am. J.\u00a0Pathol. 182: 1750\u20131768, https:\/\/doi.org\/10.1016\/j.ajpath.2013.01.034.","DOI":"10.1016\/j.ajpath.2013.01.034"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_113","doi-asserted-by":"crossref","unstructured":"Lacosta, A.M., Pascual-Lucas, M., Pesini, P., Casabona, D., P\u00e9rez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monle\u00f3n, I., et al.. (2018). Safety, tolerability and immunogenicity of an active anti-A\u03b2(40) vaccine (ABvac40) in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res. Ther. 10: 12, https:\/\/doi.org\/10.1186\/s13195-018-0340-8.","DOI":"10.1186\/s13195-018-0340-8"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_114","doi-asserted-by":"crossref","unstructured":"Lal, R., Lin, H., and Quist, A.P. (2007). Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim. Biophys. Acta 1768: 1966\u20131975, https:\/\/doi.org\/10.1016\/j.bbamem.2007.04.021.","DOI":"10.1016\/j.bbamem.2007.04.021"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_115","doi-asserted-by":"crossref","unstructured":"Lee, C.Y. and Landreth, G.E. (2010). The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) 117: 949\u2013960, https:\/\/doi.org\/10.1007\/s00702-010-0433-4.","DOI":"10.1007\/s00702-010-0433-4"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_116","doi-asserted-by":"crossref","unstructured":"Li, K., Li, J., Zheng, J., and Qin, S. (2019). Reactive astrocytes in neurodegenerative diseases. Aging Dis. 10: 664\u2013675, https:\/\/doi.org\/10.14336\/ad.2018.0720.","DOI":"10.14336\/AD.2018.0720"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_117","doi-asserted-by":"crossref","unstructured":"Li, H., Sun, B., Huang, Y., Zhang, J., Xu, X., Shen, Y., Chen, Z., Yang, J., Shen, L., Hu, Y., et al.. (2022). Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson\u2019s disease models in\u00a0vitro and vivo. Mol. Med. 28: 29, https:\/\/doi.org\/10.1186\/s10020-022-00456-x.","DOI":"10.1186\/s10020-022-00456-x"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_118","doi-asserted-by":"crossref","unstructured":"Li, H., Chen, Z., Shen, Y., Xiong, T., Chen, A., Chen, L., Ye, Y., Jiang, Q., Zhang, Y., Sun, J., et al.. (2024a). Gene therapy in A\u03b2-induced cell and mouse models of Alzheimer\u2019s disease through compensating defective mitochondrial complex I function. J.\u00a0Transl. Med. 22: 760, https:\/\/doi.org\/10.1186\/s12967-024-05571-3.","DOI":"10.1186\/s12967-024-05571-3"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_119","doi-asserted-by":"crossref","unstructured":"Li, Y.B., Fu, Q., Guo, M., Du, Y., Chen, Y., and Cheng, Y. (2024b). MicroRNAs: pioneering regulators in Alzheimer\u2019s disease pathogenesis, diagnosis, and therapy. Transl. Psychiatry 14: 367, https:\/\/doi.org\/10.1038\/s41398-024-03075-8.","DOI":"10.1038\/s41398-024-03075-8"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_120","doi-asserted-by":"crossref","unstructured":"Liao, Y.F., Wang, B.J., Cheng, H.T., Kuo, L.H., and Wolfe, M.S. (2004). Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J.\u00a0Biol. Chem. 279: 49523\u201349532, https:\/\/doi.org\/10.1074\/jbc.m402034200.","DOI":"10.1074\/jbc.M402034200"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_121","doi-asserted-by":"crossref","unstructured":"Liao, F., Jiang, H., Srivatsan, S., Xiao, Q., Lefton, K.B., Yamada, K., Mahan, T.E., Lee, J.M., Shaw, A.S., and Holtzman, D.M. (2015). Effects of CD2-associated protein deficiency on amyloid-\u03b2 in neuroblastoma cells and in an APP transgenic mouse model. Mol. Neurodegener 10: 12, https:\/\/doi.org\/10.1186\/s13024-015-0006-y.","DOI":"10.1186\/s13024-015-0006-y"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_122","doi-asserted-by":"crossref","unstructured":"Liddelow, S.A., Guttenplan, K.A., Clarke, L.E., Bennett, F.C., Bohlen, C.J., Schirmer, L., Bennett, M.L., M\u00fcnch, A.E., Chung, W.S., Peterson, T.C., et al.. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541: 481\u2013487, https:\/\/doi.org\/10.1038\/nature21029.","DOI":"10.1038\/nature21029"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_123","doi-asserted-by":"crossref","unstructured":"Liefhebber, J.M., Martier, R., Van der Zon, T., Keskin, S., Huseinovic, A., Lubelski, J., Blits, B., Petry, H., and Konstantinova, P. (2019). In-depth characterization of a mifepristone-regulated expression system for AAV5-mediated gene therapy in the liver. Mol. Ther. Methods Clin. Dev. 13: 512\u2013525, https:\/\/doi.org\/10.1016\/j.omtm.2019.05.002.","DOI":"10.1016\/j.omtm.2019.05.002"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_124","doi-asserted-by":"crossref","unstructured":"Liu, Y., Studzinski, C., Beckett, T., Guan, H., Hersh, M.A., Murphy, M.P., Klein, R., and Hersh, L.B. (2009). Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol. Ther. 17: 1381\u20131386, https:\/\/doi.org\/10.1038\/mt.2009.115.","DOI":"10.1038\/mt.2009.115"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_125","doi-asserted-by":"crossref","unstructured":"Liu, C.C., Liu, C.C., Kanekiyo, T., Xu, H., and Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9: 106\u2013118, https:\/\/doi.org\/10.1038\/nrneurol.2012.263.","DOI":"10.1038\/nrneurol.2012.263"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_126","doi-asserted-by":"crossref","unstructured":"Lustbader, J.W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al.. (2004). ABAD directly links Abeta to mitochondrial toxicity in Alzheimer\u2019s disease. Science 304: 448\u2013452, https:\/\/doi.org\/10.1126\/science.1091230.","DOI":"10.1126\/science.1091230"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_127","doi-asserted-by":"crossref","unstructured":"Ma, C., Hong, F., and Yang, S. (2022). Amyloidosis in Alzheimer\u2019s disease: pathogeny, etiology, and related therapeutic directions. Molecules 27, https:\/\/doi.org\/10.3390\/molecules27041210.","DOI":"10.3390\/molecules27041210"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_128","doi-asserted-by":"crossref","unstructured":"MacDougall, G., Brown, L.Y., Kantor, B., and Chiba-Falek, O. (2021). The path to progress preclinical studies of age-related neurodegenerative diseases: a perspective on rodent and hiPSC-derived models. Mol. Ther. 29: 949\u2013972, https:\/\/doi.org\/10.1016\/j.ymthe.2021.01.001.","DOI":"10.1016\/j.ymthe.2021.01.001"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_129","doi-asserted-by":"crossref","unstructured":"Martier, R. and Konstantinova, P. (2020). Gene therapy for neurodegenerative diseases: slowing down the ticking clock. Front Neurosci. 14: 580179, https:\/\/doi.org\/10.3389\/fnins.2020.580179.","DOI":"10.3389\/fnins.2020.580179"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_130","doi-asserted-by":"crossref","unstructured":"Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J.Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al.. (2019). Single-cell transcriptomic analysis of Alzheimer\u2019s disease. Nature 570: 332\u2013337, https:\/\/doi.org\/10.1038\/s41586-019-1195-2.","DOI":"10.1038\/s41586-019-1195-2"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_131","doi-asserted-by":"crossref","unstructured":"Matsuzaki, K. (2007). Physicochemical interactions of amyloid beta-peptide with lipid bilayers. Biochim. Biophys. Acta 1768: 1935\u20131942, https:\/\/doi.org\/10.1016\/j.bbamem.2007.02.009.","DOI":"10.1016\/j.bbamem.2007.02.009"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_132","doi-asserted-by":"crossref","unstructured":"Merighi, S., Nigro, M., Travagli, A., and Gessi, S. (2022). Microglia and Alzheimer\u2019s disease. Int. J.\u00a0Mol. Sci. 23: 12990, https:\/\/doi.org\/10.3390\/ijms232112990.","DOI":"10.3390\/ijms232112990"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_133","doi-asserted-by":"crossref","unstructured":"Michelucci, A., Heurtaux, T., Grandbarbe, L., Morga, E., and Heuschling, P. (2009). Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-\u03b2. J.\u00a0Neuroimmunol. 210: 3\u201312, https:\/\/doi.org\/10.1016\/j.jneuroim.2009.02.003.","DOI":"10.1016\/j.jneuroim.2009.02.003"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_134","unstructured":"Misra, S. (2013). Human gene therapy: a brief overview of the genetic revolution. J.\u00a0Assoc. Physicians India 61: 127\u2013133."},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_135","doi-asserted-by":"crossref","unstructured":"Mitra, S., Behbahani, H., and Eriksdotter, M. (2019). Innovative therapy for Alzheimer\u2019s disease-with focus on biodelivery of NGF. Front Neurosci. 13: 38, https:\/\/doi.org\/10.3389\/fnins.2019.00038.","DOI":"10.3389\/fnins.2019.00038"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_136","doi-asserted-by":"crossref","unstructured":"Montenegro, P., Chen, P., Kang, J., Lee, S.H., Leone, S., and Shen, J. (2023). Human Presenilin-1 delivered by AAV9 rescues impaired \u03b3-secretase activity, memory deficits, and neurodegeneration in Psen mutant mice. Proc. Natl. Acad. Sci. U. S. A. 120, https:\/\/doi.org\/10.1073\/pnas.2306714120.","DOI":"10.1073\/pnas.2306714120"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_137","doi-asserted-by":"crossref","unstructured":"Mookherjee, P., Green, P.S., Watson, G.S., Marques, M.A., Tanaka, K., Meeker, K.D., Meabon, J.S., Li, N., Zhu, P., Olson, V.G., et al.. (2011). GLT-1 loss accelerates cognitive deficit onset in an Alzheimer\u2019s disease animal model. J.\u00a0Alzheimers Dis. 26: 447\u2013455, https:\/\/doi.org\/10.3233\/jad-2011-110503.","DOI":"10.3233\/JAD-2011-110503"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_138","doi-asserted-by":"crossref","unstructured":"Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A., and Benoit, J.P. (2008). Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29: 3477\u20133496, https:\/\/doi.org\/10.1016\/j.biomaterials.2008.04.036.","DOI":"10.1016\/j.biomaterials.2008.04.036"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_139","doi-asserted-by":"crossref","unstructured":"Morroni, F. and Caccamo, A. (2024). Advances and challenges in gene therapy for Alzheimer\u2019s disease. J.\u00a0Alzheimers Dis. 101: S417\u2013s431, https:\/\/doi.org\/10.3233\/jad-230783.","DOI":"10.3233\/JAD-230783"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_140","doi-asserted-by":"crossref","unstructured":"Mossmann, D., V\u00f6gtle, F.N., Taskin, A.A., Teixeira, P.F., Ring, J., Burkhart, J.M., Burger, N., Pinho, C.M., Tadic, J., Loreth, D., et al.. (2014). Amyloid-\u03b2 peptide induces mitochondrial dysfunction by inhibition of preprotein maturation. Cell Metab. 20: 662\u2013669, https:\/\/doi.org\/10.1016\/j.cmet.2014.07.024.","DOI":"10.1016\/j.cmet.2014.07.024"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_141","doi-asserted-by":"crossref","unstructured":"M\u00fcller, U.C., Deller, T., and Korte, M. (2017). Not just amyloid: physiological functions of the amyloid precursor protein family. Nat. Rev. Neurosci. 18: 281\u2013298, https:\/\/doi.org\/10.1038\/nrn.2017.29.","DOI":"10.1038\/nrn.2017.29"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_142","doi-asserted-by":"crossref","unstructured":"Musardo, S., Therin, S., Pelucchi, S., D\u2019Andrea, L., Stringhi, R., Ribeiro, A., Manca, A., Balducci, C., Pagano, J., Sala, C., et al.. (2022). The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer\u2019s disease. Mol. Ther. 30: 2474\u20132490, https:\/\/doi.org\/10.1016\/j.ymthe.2022.03.024.","DOI":"10.1016\/j.ymthe.2022.03.024"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_143","doi-asserted-by":"crossref","unstructured":"Nanclares, C., Baraibar, A.M., Araque, A., and Kofuji, P. (2021). Dysregulation of astrocyte-neuronal communication in Alzheimer\u2019s disease. Int. J.\u00a0Mol. Sci. 22, https:\/\/doi.org\/10.3390\/ijms22157887.","DOI":"10.3390\/ijms22157887"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_144","doi-asserted-by":"crossref","unstructured":"Navarrete, M. and Araque, A. (2014). The Cajal school and the physiological role of astrocytes: a way of thinking. Front Neuroanat. 8: 33, https:\/\/doi.org\/10.3389\/fnana.2014.00033.","DOI":"10.3389\/fnana.2014.00033"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_145","doi-asserted-by":"crossref","unstructured":"Neuner, S.M., Heuer, S.E., Huentelman, M.J., O\u2019Connell, K.M.S., and Kaczorowski, C.C. (2019). Harnessing genetic complexity to enhance translatability of Alzheimer\u2019s disease mouse models: a path toward precision medicine. Neuron 101: 399\u2013411.e395, https:\/\/doi.org\/10.1016\/j.neuron.2018.11.040.","DOI":"10.1016\/j.neuron.2018.11.040"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_146","doi-asserted-by":"crossref","unstructured":"Neuner, S.M., Tcw, J., and Goate, A.M. (2020). Genetic architecture of Alzheimer\u2019s disease. Neurobiol. Dis. 143: 104976, https:\/\/doi.org\/10.1016\/j.nbd.2020.104976.","DOI":"10.1016\/j.nbd.2020.104976"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_147","doi-asserted-by":"crossref","unstructured":"Ng, R.C., Cheng, O.Y., Jian, M., Kwan, J.S., Ho, P.W., Cheng, K.K., Yeung, P.K., Zhou, L.L., Hoo, R.L., Chung, S.K., et al.. (2016). Chronic adiponectin deficiency leads to Alzheimer\u2019s disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice. Mol. Neurodegener 11: 71, https:\/\/doi.org\/10.1186\/s13024-016-0136-x.","DOI":"10.1186\/s13024-016-0136-x"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_148","unstructured":"Ng, R.C.L., Jian, M., Yick, L.W., Bunting, M., Kwan, J.S.C., Chung, S.K., and Chan, K.H. (2020). Adiponectin gene therapy for Alzheimer disease in a mouse model: abridged secondary publication. Hong Kong Med. J. 26 (Suppl 8): 27\u201333."},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_149","doi-asserted-by":"crossref","unstructured":"Ng, R.C., Jian, M., Ma, O.K., Xiang, A.W., Bunting, M., Kwan, J.S., Wong, C.W., Yick, L.W., Chung, S.K., Lam, K.S., et al.. (2024). Liver-specific adiponectin gene therapy suppresses microglial NLRP3-inflammasome activation for treating Alzheimer\u2019s disease. J.\u00a0Neuroinflammation 21: 77, https:\/\/doi.org\/10.1186\/s12974-024-03066-y.","DOI":"10.1186\/s12974-024-03066-y"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_150","doi-asserted-by":"crossref","unstructured":"Nguyen, K.V. (2019). \u03b2-Amyloid precursor protein (APP) and the human diseases. AIMS Neurosci. 6: 273\u2013281, https:\/\/doi.org\/10.3934\/Neuroscience.2019.4.273.","DOI":"10.3934\/Neuroscience.2019.4.273"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_151","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T., Nguyen, T.T.D., Nguyen, T.K.O., Vo, T.K., and Vo, V.G. (2021). Advances in developing therapeutic strategies for Alzheimer\u2019s disease. Biomed. Pharmacother. 139: 111623, https:\/\/doi.org\/10.1016\/j.biopha.2021.111623.","DOI":"10.1016\/j.biopha.2021.111623"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_152","doi-asserted-by":"crossref","unstructured":"Nickerson, D.A., Taylor, S.L., Fullerton, S.M., Weiss, K.M., Clark, A.G., Steng\u00e5rd, J.H., Salomaa, V., Boerwinkle, E., and Sing, C.F. (2000). Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. Genome Res. 10: 1532\u20131545, https:\/\/doi.org\/10.1101\/gr.146900.","DOI":"10.1101\/gr.146900"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_153","doi-asserted-by":"crossref","unstructured":"Oishi, A., Gbahou, F., and Jockers, R. (2021). Melatonin receptors, brain functions, and therapies. Handb. Clin. Neurol. 179: 345\u2013356, https:\/\/doi.org\/10.1016\/b978-0-12-819975-6.00022-4.","DOI":"10.1016\/B978-0-12-819975-6.00022-4"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_259","doi-asserted-by":"crossref","unstructured":"Ooi, L., Dottori, M., Cook, A.L., Engel, M., Gautam, V., Grubman, A., Hern\u00e1ndez, D., King, A.E., Maksour, S., Targa Dias Anastacio, H., et al.. (2020). If human brain organoids are the answer to understanding dementia, what are the questions? Neuroscientist 26: 438\u2013454, https:\/\/doi.org\/10.1177\/1073858420912404.","DOI":"10.1177\/1073858420912404"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_154","doi-asserted-by":"crossref","unstructured":"Ortiz-Virumbrales, M., Moreno, C.L., Kruglikov, I., Marazuela, P., Sproul, A., Jacob, S., Zimmer, M., Paull, D., Zhang, B., Schadt, E.E., et al.. (2017). CRISPR\/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer\u2019s PSEN2 (N141I) neurons. Acta Neuropathol. Commun. 5: 77, https:\/\/doi.org\/10.1186\/s40478-017-0475-z.","DOI":"10.1186\/s40478-017-0475-z"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_155","doi-asserted-by":"crossref","unstructured":"Owens, L.V., Benedetto, A., Dawson, N., Gaffney, C.J., and Parkin, E.T. (2021). Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer\u2019s disease. Brain Res. 1753: 147264, https:\/\/doi.org\/10.1016\/j.brainres.2020.147264.","DOI":"10.1016\/j.brainres.2020.147264"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_156","doi-asserted-by":"crossref","unstructured":"Pantelidis, P., Lambert-Hammill, M., and Wierzbicki, A.S. (2003). Simple sequence-specific-primer-PCR method to identify the three main apolipoprotein E haplotypes. Clin. Chem. 49: 1945\u20131948, https:\/\/doi.org\/10.1373\/clinchem.2003.021683.","DOI":"10.1373\/clinchem.2003.021683"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_157","doi-asserted-by":"crossref","unstructured":"Pardo-Moreno, T., Gonz\u00e1lez-Acedo, A., Rivas-Dom\u00ednguez, A., Garc\u00eda-Morales, V., Garc\u00eda-Cozar, F.J., Ramos-Rodr\u00edguez, J.J., and Melguizo-Rodr\u00edguez, L. (2022). Therapeutic approach to Alzheimer\u2019s disease: current treatments and new perspectives. Pharmaceutics. 14, https:\/\/doi.org\/10.3390\/pharmaceutics14061117.","DOI":"10.3390\/pharmaceutics14061117"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_158","doi-asserted-by":"crossref","unstructured":"Parhizkar, S., Arzberger, T., Brendel, M., Kleinberger, G., Deussing, M., Focke, C., Nuscher, B., Xiong, M., Ghasemigharagoz, A., Katzmarski, N., et al.. (2019). Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci. 22: 191\u2013204, https:\/\/doi.org\/10.1038\/s41593-018-0296-9.","DOI":"10.1038\/s41593-018-0296-9"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_159","doi-asserted-by":"crossref","unstructured":"Park, H. and Kim, J. (2022). Activation of melatonin receptor 1 by CRISPR-Cas9 activator ameliorates cognitive deficits in an Alzheimer\u2019s disease mouse model. J.\u00a0Pineal Res. 72: e12787, https:\/\/doi.org\/10.1111\/jpi.12787.","DOI":"10.1111\/jpi.12787"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_160","doi-asserted-by":"crossref","unstructured":"Park, H., Oh, J., Shim, G., Cho, B., Chang, Y., Kim, S., Baek, S., Kim, H., Shin, J., Choi, H., et al.. (2019). In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer\u2019s disease. Nat. Neurosci. 22: 524\u2013528, https:\/\/doi.org\/10.1038\/s41593-019-0352-0.","DOI":"10.1038\/s41593-019-0352-0"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_161","doi-asserted-by":"crossref","unstructured":"Park, S.M., Kang, T.I., and So, J.S. (2021). Roles of XBP1s in transcriptional regulation of target genes. Biomedicines 9, https:\/\/doi.org\/10.3390\/biomedicines9070791.","DOI":"10.3390\/biomedicines9070791"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_162","doi-asserted-by":"crossref","unstructured":"Parodi, J., Sep\u00falveda, F.J., Roa, J., Opazo, C., Inestrosa, N.C., and Aguayo, L.G. (2010). Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J.\u00a0Biol. Chem. 285: 2506\u20132514, https:\/\/doi.org\/10.1074\/jbc.M109.030023.","DOI":"10.1074\/jbc.M109.030023"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_163","doi-asserted-by":"crossref","unstructured":"Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F.T., and Arab-Tehrany, E. (2022). Alzheimer\u2019s disease: treatment strategies and their limitations. Int. J.\u00a0Mol. Sci. 23, https:\/\/doi.org\/10.3390\/ijms232213954.","DOI":"10.3390\/ijms232213954"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_164","doi-asserted-by":"crossref","unstructured":"Pekny, M., Pekna, M., Messing, A., Steinh\u00e4user, C., Lee, J.M., Parpura, V., Hol, E.M., Sofroniew, M.V., and Verkhratsky, A. (2016). Astrocytes: a central element in neurological diseases. Acta Neuropathol. 131: 323\u2013345, https:\/\/doi.org\/10.1007\/s00401-015-1513-1.","DOI":"10.1007\/s00401-015-1513-1"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_165","doi-asserted-by":"crossref","unstructured":"Peron, R., Vatanabe, I.P., Manzine, P.R., Camins, A., and Cominetti, M.R. (2018). Alpha-secretase ADAM10 regulation: insights into Alzheimer\u2019s disease treatment. Pharmaceuticals (Basel) 11.","DOI":"10.3390\/ph11010012"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_166","doi-asserted-by":"crossref","unstructured":"Petersen, R.C., Parisi, J.E., Dickson, D.W., Johnson, K.A., Knopman, D.S., Boeve, B.F., Jicha, G.A., Ivnik, R.J., Smith, G.E., Tangalos, E.G., et al.. (2006). Neuropathologic features of amnestic mild cognitive impairment. Arch. Neurol. 63: 665\u2013672, https:\/\/doi.org\/10.1001\/archneur.63.5.665.","DOI":"10.1001\/archneur.63.5.665"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_167","doi-asserted-by":"crossref","unstructured":"Petrushina, I., Hovakimyan, A., Harahap-Carrillo, I.S., Davtyan, H., Antonyan, T., Chailyan, G., Kazarian, K., Antonenko, M., Jullienne, A., Hamer, M.M., et al.. (2020). Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. Neurobiol. Dis. 139: 104823, https:\/\/doi.org\/10.1016\/j.nbd.2020.104823.","DOI":"10.1016\/j.nbd.2020.104823"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_168","doi-asserted-by":"crossref","unstructured":"Piguet, F., de Saint Denis, T., Audouard, E., Beccaria, K., Andr\u00e9, A., Wurtz, G., Schatz, R., Alves, S., Sevin, C., Zerah, M., et al.. (2021). The challenge of gene therapy for neurological diseases: strategies and tools to achieve efficient delivery to the central nervous system. Hum. Gene Ther. 32: 349\u2013374, https:\/\/doi.org\/10.1089\/hum.2020.105.","DOI":"10.1089\/hum.2020.105"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_169","doi-asserted-by":"crossref","unstructured":"Pizzo, P., Basso, E., Filadi, R., Greotti, E., Leparulo, A., Pendin, D., Redolfi, N., Rossini, M., Vajente, N., Pozzan, T., et al.. (2020). Presenilin-2 and calcium handling: molecules, organelles, cells and brain networks. Cells 9: 2166, https:\/\/doi.org\/10.3390\/cells9102166.","DOI":"10.3390\/cells9102166"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_170","doi-asserted-by":"crossref","unstructured":"Preman, P., Alfonso-Triguero, M., Alberdi, E., Verkhratsky, A., and Arranz, A.M. (2021). Astrocytes in Alzheimer\u2019s disease: pathological significance and molecular pathways. Cells. 10, https:\/\/doi.org\/10.3390\/cells10030540.","DOI":"10.20944\/preprints202102.0230.v1"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_171","doi-asserted-by":"crossref","unstructured":"Puranik, N., Yadav, D., Chauhan, P.S., Kwak, M., and Jin, J.O. (2021). Exploring the role of gene therapy for neurological disorders. Curr. Gene Ther. 21: 11\u201322, https:\/\/doi.org\/10.2174\/1566523220999200917114101.","DOI":"10.2174\/1566523220999200917114101"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_172","doi-asserted-by":"crossref","unstructured":"Qin, Q., Teng, Z., Liu, C., Li, Q., Yin, Y., and Tang, Y. (2021). TREM2, microglia, and Alzheimer\u2019s disease. Mech. Ageing Dev. 195: 111438, https:\/\/doi.org\/10.1016\/j.mad.2021.111438.","DOI":"10.1016\/j.mad.2021.111438"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_173","doi-asserted-by":"crossref","unstructured":"Rafii, M.S., Tuszynski, M.H., Thomas, R.G., Barba, D., Brewer, J.B., Rissman, R.A., Siffert, J., and Aisen, P.S. (2018). Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with alzheimer disease: a randomized clinical trial. JAMA Neurol. 75: 834\u2013841, https:\/\/doi.org\/10.1001\/jamaneurol.2018.0233.","DOI":"10.1001\/jamaneurol.2018.0233"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_174","doi-asserted-by":"crossref","unstructured":"Ramakrishnan, V., Akram Husain, R.S., and Ahmed, S.S.S.J. (2017). PSEN1 gene polymorphisms in Caucasian Alzheimer\u2019s disease: a meta-analysis. Clin. Chim. Acta 473: 65\u201370, https:\/\/doi.org\/10.1016\/j.cca.2017.08.016.","DOI":"10.1016\/j.cca.2017.08.016"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_175","doi-asserted-by":"crossref","unstructured":"Rauch, J.N., Luna, G., Guzman, E., Audouard, M., Challis, C., Sibih, Y.E., Leshuk, C., Hernandez, I., Wegmann, S., Hyman, B.T., et al.. (2020). LRP1 is a master regulator of tau uptake and spread. Nature 580: 381\u2013385, https:\/\/doi.org\/10.1038\/s41586-020-2156-5.","DOI":"10.1038\/s41586-020-2156-5"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_176","doi-asserted-by":"crossref","unstructured":"Raulin, A.C., Doss, S.V., Trottier, Z.A., Ikezu, T.C., Bu, G., and Liu, C.C. (2022). ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol. Neurodegener 17: 72, https:\/\/doi.org\/10.1186\/s13024-022-00574-4.","DOI":"10.1186\/s13024-022-00574-4"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_177","doi-asserted-by":"crossref","unstructured":"Ries, M. and Sastre, M. (2016). Mechanisms of A\u03b2 clearance and degradation by glial cells. Front Aging Neurosci. 8: 160, https:\/\/doi.org\/10.3389\/fnagi.2016.00160.","DOI":"10.3389\/fnagi.2016.00160"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_178","doi-asserted-by":"crossref","unstructured":"Rodrigues, B.D.S., Kanekiyo, T., and Singh, J. (2020). Nerve growth factor gene delivery across the blood-brain barrier to reduce beta amyloid accumulation in AD mice. Mol. Pharm. 17: 2054\u20132063, https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00218.","DOI":"10.1021\/acs.molpharmaceut.0c00218"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_179","doi-asserted-by":"crossref","unstructured":"Rosen, R.F., Tomidokoro, Y., Farberg, A.S., Dooyema, J., Ciliax, B., Preuss, T.M., Neubert, T.A., Ghiso, J.A., LeVine, H., and Walker, L.C. (2016). Comparative pathobiology of \u03b2-amyloid and the unique susceptibility of humans to Alzheimer\u2019s disease. Neurobiol. Aging 44: 185\u2013196, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.04.019.","DOI":"10.1016\/j.neurobiolaging.2016.04.019"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_181","doi-asserted-by":"crossref","unstructured":"Ruetz, T.J., Pogson, A.N., Kashiwagi, C.M., Gagnon, S.D., Morton, B., Sun, E.D., Na, J., Yeo, R.W., Leeman, D.S., Morgens, D.W., et al.. (2024). CRISPR\u2013Cas9 screens reveal regulators of ageing in neural stem cells. Nature 634: 1150\u20131159, https:\/\/doi.org\/10.1038\/s41586-024-07972-2.","DOI":"10.1038\/s41586-024-07972-2"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_182","doi-asserted-by":"crossref","unstructured":"Saidi, L.J., Polydoro, M., Kay, K.R., Sanchez, L., Mandelkow, E.M., Hyman, B.T., and Spires-Jones, T.L. (2015). Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes. J.\u00a0Alzheimers Dis. 44: 937\u2013947, https:\/\/doi.org\/10.3233\/jad-142094.","DOI":"10.3233\/JAD-142094"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_183","doi-asserted-by":"crossref","unstructured":"Sayed, N., Allawadhi, P., Khurana, A., Singh, V., Navik, U., Pasumarthi, S.K., Khurana, I., Banothu, A.K., Weiskirchen, R., and Bharani, K.K. (2022). Gene therapy: comprehensive overview and therapeutic applications. Life Sci. 294: 120375, https:\/\/doi.org\/10.1016\/j.lfs.2022.120375.","DOI":"10.1016\/j.lfs.2022.120375"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_184","doi-asserted-by":"crossref","unstructured":"Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Ch\u00e9telat, G., Teunissen, C.E., Cummings, J., and van der Flier, W.M. (2021). Alzheimer\u2019s disease. Lancet 397: 1577\u20131590, https:\/\/doi.org\/10.1016\/s0140-6736(20)32205-4.","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_185","doi-asserted-by":"crossref","unstructured":"Schindowski, K., Belarbi, K., and Bu\u00e9e, L. (2008). Neurotrophic factors in Alzheimer\u2019s disease: role of axonal transport. Genes Brain Behav 7 (Suppl 1): 43\u201356, https:\/\/doi.org\/10.1111\/j.1601-183X.2007.00378.x.","DOI":"10.1111\/j.1601-183X.2007.00378.x"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_186","doi-asserted-by":"crossref","unstructured":"Schlepckow, K., Monroe, K.M., Kleinberger, G., Cantuti-Castelvetri, L., Parhizkar, S., Xia, D., Willem, M., Werner, G., Pettkus, N., Brunner, B., et al.. (2020). Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. 12: e11227, https:\/\/doi.org\/10.15252\/emmm.201911227.","DOI":"10.15252\/emmm.201911227"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_187","doi-asserted-by":"crossref","unstructured":"Sehar, U., Rawat, P., Reddy, A.P., Kopel, J., and Reddy, P.H. (2022). Amyloid beta in aging and Alzheimer\u2019s disease. Int. J.\u00a0Mol. Sci. 23, https:\/\/doi.org\/10.3390\/ijms232112924.","DOI":"10.3390\/ijms232112924"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_188","doi-asserted-by":"crossref","unstructured":"Selkoe, D.J. and Hardy, J. (2016). The amyloid hypothesis of Alzheimer\u2019s disease at 25\u00a0years. EMBO Mol. Med. 8: 595\u2013608, https:\/\/doi.org\/10.15252\/emmm.201606210.","DOI":"10.15252\/emmm.201606210"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_189","doi-asserted-by":"crossref","unstructured":"Serrano-Pozo, A., Qian, J., Monsell, S.E., Betensky, R.A., and Hyman, B.T. (2015). APOE\u03b52 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol. 77: 917\u2013929, https:\/\/doi.org\/10.1002\/ana.24369.","DOI":"10.1002\/ana.24369"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_190","doi-asserted-by":"crossref","unstructured":"Serrano-Pozo, A., Das, S., and Hyman, B.T. (2021). APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 20: 68\u201380, https:\/\/doi.org\/10.1016\/s1474-4422(20)30412-9.","DOI":"10.1016\/S1474-4422(20)30412-9"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_191","doi-asserted-by":"crossref","unstructured":"Seshadri, S., Fitzpatrick, A.L., Ikram, M.A., DeStefano, A.L., Gudnason, V., Boada, M., Bis, J.C., Smith, A.V., Carassquillo, M.M., Lambert, J.C., et al.. (2010). Genome-wide analysis of genetic loci associated with Alzheimer disease. Jama 303: 1832\u20131840, https:\/\/doi.org\/10.1001\/jama.2010.574.","DOI":"10.1001\/jama.2010.574"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_192","doi-asserted-by":"crossref","unstructured":"Sevigny, J., Chiao, P., Bussi\u00e8re, T., Weinreb, P.H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al.. (2016). The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537: 50\u201356, https:\/\/doi.org\/10.1038\/nature19323.","DOI":"10.1038\/nature19323"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_193","doi-asserted-by":"crossref","unstructured":"Shankar, G.M., Leissring, M.A., Adame, A., Sun, X., Spooner, E., Masliah, E., Selkoe, D.J., Lemere, C.A., and Walsh, D.M. (2009). Biochemical and immunohistochemical analysis of an Alzheimer\u2019s disease mouse model reveals the presence of multiple cerebral A\u03b2 assembly forms throughout life. Neurobiol. Dis. 36: 293\u2013302, https:\/\/doi.org\/10.1016\/j.nbd.2009.07.021.","DOI":"10.1016\/j.nbd.2009.07.021"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_194","doi-asserted-by":"crossref","unstructured":"Shen, J. and Kelleher, R.J.3rd (2007). The presenilin hypothesis of Alzheimer\u2019s disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. U. S. A. 104: 403\u2013409, https:\/\/doi.org\/10.1073\/pnas.0608332104.","DOI":"10.1073\/pnas.0608332104"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_195","doi-asserted-by":"crossref","unstructured":"Shi, Y., Yamada, K., Liddelow, S.A., Smith, S.T., Zhao, L., Luo, W., Tsai, R.M., Spina, S., Grinberg, L.T., Rojas, J.C., et al.. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549: 523\u2013527, https:\/\/doi.org\/10.1038\/nature24016.","DOI":"10.1038\/nature24016"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_196","doi-asserted-by":"crossref","unstructured":"Shi, Y., Manis, M., Long, J., Wang, K., Sullivan, P.M., Remolina Serrano, J., Hoyle, R., and Holtzman, D.M. (2019). Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J.\u00a0Exp. Med. 216: 2546\u20132561, https:\/\/doi.org\/10.1084\/jem.20190980.","DOI":"10.1084\/jem.20190980"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_197","doi-asserted-by":"crossref","unstructured":"Shineman, D.W., Basi, G.S., Bizon, J.L., Colton, C.A., Greenberg, B.D., Hollister, B.A., Lincecum, J., Leblanc, G.G., Lee, L.B., Luo, F., et al.. (2011). Accelerating drug discovery for Alzheimer\u2019s disease: best practices for preclinical animal studies. Alzheimers Res. Ther. 3: 28, https:\/\/doi.org\/10.1186\/alzrt90.","DOI":"10.1186\/alzrt90"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_198","doi-asserted-by":"crossref","unstructured":"Shirley, J.L., de Jong, Y.P., Terhorst, C., and Herzog, R.W. (2020). Immune responses to viral gene therapy vectors. Mol. Ther. 28: 709\u2013722, https:\/\/doi.org\/10.1016\/j.ymthe.2020.01.001.","DOI":"10.1016\/j.ymthe.2020.01.001"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_199","doi-asserted-by":"crossref","unstructured":"Shulman, J.M., Imboywa, S., Giagtzoglou, N., Powers, M.P., Hu, Y., Devenport, D., Chipendo, P., Chibnik, L.B., Diamond, A., Perrimon, N., et al.. (2014). Functional screening in Drosophila identifies Alzheimer\u2019s disease susceptibility genes and implicates Tau-mediated mechanisms. Hum. Mol. Genet. 23: 870\u2013877, https:\/\/doi.org\/10.1093\/hmg\/ddt478.","DOI":"10.1093\/hmg\/ddt478"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_200","doi-asserted-by":"crossref","unstructured":"Singh, A.K. and Pati, U. (2015). CHIP stabilizes amyloid precursor protein via proteasomal degradation and p53-mediated trans-repression of \u03b2-secretase. Aging Cell 14: 595\u2013604, https:\/\/doi.org\/10.1111\/acel.12335.","DOI":"10.1111\/acel.12335"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_201","doi-asserted-by":"crossref","unstructured":"Singh, K., Sethi, P., Datta, S., Chaudhary, J.S., Kumar, S., Jain, D., Gupta, J.K., Kumar, S., Guru, A., and Panda, S.P. (2024). Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases. Ageing Res. Rev. 98: 102321, https:\/\/doi.org\/10.1016\/j.arr.2024.102321.","DOI":"10.1016\/j.arr.2024.102321"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_202","doi-asserted-by":"crossref","unstructured":"Sirisi, S., S\u00e1nchez-Aced, \u00c9., Belbin, O., and Lle\u00f3, A. (2024). APP dyshomeostasis in the pathogenesis of Alzheimer\u2019s disease: implications for current drug targets. Alzheimer\u2019s Res. Ther. 16: 144, https:\/\/doi.org\/10.1186\/s13195-024-01504-w.","DOI":"10.1186\/s13195-024-01504-w"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_203","doi-asserted-by":"crossref","unstructured":"Spires-Jones, T.L. and Hyman, B.T. (2014). The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease. Neuron 82: 756\u2013771, https:\/\/doi.org\/10.1016\/j.neuron.2014.05.004.","DOI":"10.1016\/j.neuron.2014.05.004"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_204","doi-asserted-by":"crossref","unstructured":"Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., and Roses, A.D. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90: 1977\u20131981, https:\/\/doi.org\/10.1073\/pnas.90.5.1977.","DOI":"10.1073\/pnas.90.5.1977"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_205","doi-asserted-by":"crossref","unstructured":"Stutzmann, G.E., Caccamo, A., LaFerla, F.M., and Parker, I. (2004). Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer\u2019s-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J.\u00a0Neurosci. 24: 508\u2013513, https:\/\/doi.org\/10.1523\/jneurosci.4386-03.2004.","DOI":"10.1523\/JNEUROSCI.4386-03.2004"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_206","doi-asserted-by":"crossref","unstructured":"Suh, J., Choi, S.H., Romano, D.M., Gannon, M.A., Lesinski, A.N., Kim, D.Y., and Tanzi, R.E. (2013). ADAM10 missense mutations potentiate \u03b2-amyloid accumulation by impairing prodomain chaperone function. Neuron 80: 385\u2013401, https:\/\/doi.org\/10.1016\/j.neuron.2013.08.035.","DOI":"10.1016\/j.neuron.2013.08.035"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_207","doi-asserted-by":"crossref","unstructured":"Sun, J., Carlson-Stevermer, J., Das, U., Shen, M., Delenclos, M., Snead, A.M., Koo, S.Y., Wang, L., Qiao, D., Loi, J., et al.. (2019). CRISPR\/Cas9 editing of APP C-terminus attenuates \u03b2-cleavage and promotes \u03b1-cleavage. Nat. Commun. 10: 53, https:\/\/doi.org\/10.1038\/s41467-018-07971-8.","DOI":"10.1038\/s41467-018-07971-8"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_208","doi-asserted-by":"crossref","unstructured":"Suzuki, K., Iwata, A., and Iwatsubo, T. (2017). The past, present, and future of disease-modifying therapies for Alzheimer\u2019s disease. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93: 757\u2013771, https:\/\/doi.org\/10.2183\/pjab.93.048.","DOI":"10.2183\/pjab.93.048"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_209","doi-asserted-by":"crossref","unstructured":"Swardfager, W., Lanct\u00f4t, K., Rothenburg, L., Wong, A., Cappell, J., and Herrmann, N. (2010). A meta-analysis of cytokines in Alzheimer\u2019s disease. Biol. Psychiatry 68: 930\u2013941, https:\/\/doi.org\/10.1016\/j.biopsych.2010.06.012.","DOI":"10.1016\/j.biopsych.2010.06.012"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_210","doi-asserted-by":"crossref","unstructured":"Tackenberg, C. and Nitsch, R.M. (2019). The secreted APP ectodomain sAPP\u03b1, but not sAPP\u03b2, protects neurons against A\u03b2 oligomer-induced dendritic spine loss and increased tau phosphorylation. Mol Brain 12: 27, https:\/\/doi.org\/10.1186\/s13041-019-0447-2.","DOI":"10.1186\/s13041-019-0447-2"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_211","doi-asserted-by":"crossref","unstructured":"Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Yamaguchi, H., Sugihara, S., et al.. (1998). Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad. Sci. U. S. A. 95: 9637\u20139641, https:\/\/doi.org\/10.1073\/pnas.95.16.9637.","DOI":"10.1073\/pnas.95.16.9637"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_212","doi-asserted-by":"crossref","unstructured":"Takuma, K., Yao, J., Huang, J., Xu, H., Chen, X., Luddy, J., Trillat, A.C., Stern, D.M., Arancio, O., and Yan, S.S. (2005). ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. Faseb J. 19: 597\u2013598, https:\/\/doi.org\/10.1096\/fj.04-2582fje.","DOI":"10.1096\/fj.04-2582fje"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_213","doi-asserted-by":"crossref","unstructured":"Tao, Q.Q., Chen, Y.C., and Wu, Z.Y. (2019). The role of CD2AP in the pathogenesis of Alzheimer\u2019s disease. Aging Dis. 10: 901\u2013907, https:\/\/doi.org\/10.14336\/ad.2018.1025.","DOI":"10.14336\/AD.2018.1025"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_214","doi-asserted-by":"crossref","unstructured":"Tateno, H., Li, H., Schur, M.J., Bovin, N., Crocker, P.R., Wakarchuk, W.W., and Paulson, J.C. (2007). Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol. Cell. Biol. 27: 5699\u20135710, https:\/\/doi.org\/10.1128\/mcb.00383-07.","DOI":"10.1128\/MCB.00383-07"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_215","doi-asserted-by":"crossref","unstructured":"Tedeschi, D.V., da Cunha, A.F., Cominetti, M.R., and Pedroso, R.V. (2021). Efficacy of gene therapy to restore cognition in Alzheimer\u2019s disease: a systematic review. Curr. Gene Ther. 21: 246\u2013257, https:\/\/doi.org\/10.2174\/1566523221666210120091146.","DOI":"10.2174\/1566523221666210120091146"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_216","doi-asserted-by":"crossref","unstructured":"Thal, D.R., R\u00fcb, U., Orantes, M., and Braak, H. (2002). Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791\u20131800, https:\/\/doi.org\/10.1212\/wnl.58.12.1791.","DOI":"10.1212\/WNL.58.12.1791"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_217","doi-asserted-by":"crossref","unstructured":"Thomas, M. and Klibanov, A.M. (2003). Non-viral gene therapy: polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol. 62: 27\u201334, https:\/\/doi.org\/10.1007\/s00253-003-1321-8.","DOI":"10.1007\/s00253-003-1321-8"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_218","doi-asserted-by":"crossref","unstructured":"Tim\u00f3n-G\u00f3mez, A., N\u00fdvltov\u00e1, E., Abriata, L.A., Vila, A.J., Hosler, J., and Barrientos, A. (2018). Mitochondrial cytochrome c oxidase biogenesis: recent developments. Semin. Cell Dev. Biol. 76: 163\u2013178, https:\/\/doi.org\/10.1016\/j.semcdb.2017.08.055.","DOI":"10.1016\/j.semcdb.2017.08.055"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_219","doi-asserted-by":"crossref","unstructured":"Trejo-Lopez, J.A., Yachnis, A.T., and Prokop, S. (2022). Neuropathology of Alzheimer\u2019s disease. Neurotherapeutics 19: 173\u2013185, https:\/\/doi.org\/10.1007\/s13311-021-01146-y.","DOI":"10.1007\/s13311-021-01146-y"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_220","doi-asserted-by":"crossref","unstructured":"Tuszynski, M.H., Yang, J.H., Barba, D., U, H.S., Bakay, R.A., Pay, M.M., Masliah, E., Conner, J.M., Kobalka, P., Roy, S., et al.. (2015). Nerve growth factor gene therapy: activation of neuronal responses in alzheimer disease. JAMA Neurol. 72: 1139\u20131147, https:\/\/doi.org\/10.1001\/jamaneurol.2015.1807.","DOI":"10.1001\/jamaneurol.2015.1807"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_221","doi-asserted-by":"crossref","unstructured":"Ulrich, J.D., Ulland, T.K., Mahan, T.E., Nystr\u00f6m, S., Nilsson, K.P., Song, W.M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., et al.. (2018). ApoE facilitates the microglial response to amyloid plaque pathology. J.\u00a0Exp. Med. 215: 1047\u20131058, https:\/\/doi.org\/10.1084\/jem.20171265.","DOI":"10.1084\/jem.20171265"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_222","doi-asserted-by":"crossref","unstructured":"Uyemura, K., Castle, S.C., and Makinodan, T. (2002). The frail elderly: role of dendritic cells in the susceptibility of infection. Mech. Ageing Dev. 123: 955\u2013962, https:\/\/doi.org\/10.1016\/s0047-6374(02)00033-7.","DOI":"10.1016\/S0047-6374(02)00033-7"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_223","doi-asserted-by":"crossref","unstructured":"Valiukas, Z., Ephraim, R., Tangalakis, K., Davidson, M., Apostolopoulos, V., and Feehan, J. (2022). Immunotherapies for Alzheimer\u2019s disease-A review. Vaccines (Basel) 10, https:\/\/doi.org\/10.3390\/vaccines10091527.","DOI":"10.3390\/vaccines10091527"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_224","doi-asserted-by":"crossref","unstructured":"Vodovotz, Y., Lucia, M.S., Flanders, K.C., Chesler, L., Xie, Q.W., Smith, T.W., Weidner, J., Mumford, R., Webber, R., Nathan, C., et al.. (1996). Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer\u2019s disease. J.\u00a0Exp. Med. 184: 1425\u20131433, https:\/\/doi.org\/10.1084\/jem.184.4.1425.","DOI":"10.1084\/jem.184.4.1425"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_225","doi-asserted-by":"crossref","unstructured":"Walther, W. and Stein, U. (2000). Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60: 249\u2013271, https:\/\/doi.org\/10.2165\/00003495-200060020-00002.","DOI":"10.2165\/00003495-200060020-00002"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_226","doi-asserted-by":"crossref","unstructured":"Wang, D.S., Dickson, D.W., and Malter, J.S. (2006). beta-Amyloid degradation and Alzheimer\u2019s disease. J.\u00a0Biomed. Biotechnol. 2006: 58406, https:\/\/doi.org\/10.1155\/jbb\/2006\/58406.","DOI":"10.1155\/JBB\/2006\/58406"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_227","doi-asserted-by":"crossref","unstructured":"Wang, C.Y., Finstad, C.L., Walfield, A.M., Sia, C., Sokoll, K.K., Chang, T.Y., Fang, X.D., Hung, C.H., Hutter-Paier, B., and Windisch, M. (2007). Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer\u2019s disease. Vaccine 25: 3041\u20133052, https:\/\/doi.org\/10.1016\/j.vaccine.2007.01.031.","DOI":"10.1016\/j.vaccine.2007.01.031"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_228","doi-asserted-by":"crossref","unstructured":"Wang, C., Najm, R., Xu, Q., Jeong, D.E., Walker, D., Balestra, M.E., Yoon, S.Y., Yuan, H., Li, G., Miller, Z.A., et al.. (2018). Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med. 24: 647\u2013657, https:\/\/doi.org\/10.1038\/s41591-018-0004-z.","DOI":"10.1038\/s41591-018-0004-z"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_229","doi-asserted-by":"crossref","unstructured":"Wang, P., Yang, P., Qian, K., Li, Y., Xu, S., Meng, R., Guo, Q., Cheng, Y., Cao, J., Xu, M., et al.. (2022). Precise gene delivery systems with detachable albumin shell remodeling dysfunctional microglia by TREM2 for treatment of Alzheimer\u2019s disease. Biomaterials 281: 121360, https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121360.","DOI":"10.1016\/j.biomaterials.2021.121360"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_230","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wang, X., Xie, R., Burger, J.C., Tong, Y., and Gong, S. (2023). Overcoming the blood-brain barrier for gene therapy via systemic administration of GSH-responsive silica nanocapsules. Adv. Mater. 35: e2208018, https:\/\/doi.org\/10.1002\/adma.202208018.","DOI":"10.1002\/adma.202208018"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_231","doi-asserted-by":"crossref","unstructured":"Wang, H., Shi, C., Jiang, L., Liu, X., Tang, R., and Tang, M. (2024a). Neuroimaging techniques, gene therapy, and gut microbiota: Frontier advances and integrated applications in Alzheimer\u2019s Disease research. Front Aging Neurosci. 16: 1485657, https:\/\/doi.org\/10.3389\/fnagi.2024.1485657.","DOI":"10.3389\/fnagi.2024.1485657"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_232","doi-asserted-by":"crossref","unstructured":"Wang, X., Xie, Y., Fan, X., Wu, X., Wang, D., and Zhu, L. (2024b). Intermittent hypoxia training enhances A\u03b2 endocytosis by plaque associated microglia via VPS35-dependent TREM2 recycling in murine Alzheimer\u2019s disease. Alzheimers Res. Ther. 16: 121, https:\/\/doi.org\/10.1186\/s13195-024-01489-6.","DOI":"10.1186\/s13195-024-01489-6"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_233","doi-asserted-by":"crossref","unstructured":"Wei, M., Wu, T., and Chen, N. (2024). Bridging neurotrophic factors and\u00a0bioactive peptides to Alzheimer\u2019s disease. Ageing Res. Rev. 94: 102177, https:\/\/doi.org\/10.1016\/j.arr.2023.102177.","DOI":"10.1016\/j.arr.2023.102177"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_234","doi-asserted-by":"crossref","unstructured":"Weisgraber, K.H. (1990). Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J.\u00a0Lipid Res. 31: 1503\u20131511, https:\/\/doi.org\/10.1016\/s0022-2275(20)42621-5.","DOI":"10.1016\/S0022-2275(20)42621-5"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_235","doi-asserted-by":"crossref","unstructured":"Westermark, P., Benson, M.D., Buxbaum, J.N., Cohen, A.S., Frangione, B., Ikeda, S., Masters, C.L., Merlini, G., Saraiva, M.J., and Sipe, J.D. (2007). A primer of amyloid nomenclature. Amyloid 14: 179\u2013183, https:\/\/doi.org\/10.1080\/13506120701460923.","DOI":"10.1080\/13506120701460923"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_236","doi-asserted-by":"crossref","unstructured":"Wilkins, H.M. (2023). Interactions between amyloid, amyloid precursor protein, and mitochondria. Biochem. Soc. Trans. 51: 173\u2013182, https:\/\/doi.org\/10.1042\/bst20220518.","DOI":"10.1042\/BST20220518"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_237","doi-asserted-by":"crossref","unstructured":"Winblad, B. and Machado, J.C. (2008). Use of rivastigmine transdermal patch in the treatment of Alzheimer\u2019s disease. Expert Opin. Drug Deliv. 5: 1377\u20131386, https:\/\/doi.org\/10.1517\/17425240802542690.","DOI":"10.1517\/17425240802542690"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_238","doi-asserted-by":"crossref","unstructured":"Wi\u00dffeld, J., Nozaki, I., Mathews, M., Raschka, T., Ebeling, C., Hornung, V., Br\u00fcstle, O., and Neumann, H. (2021). Deletion of Alzheimer\u2019s disease-associated CD33 results in an inflammatory human microglia phenotype. Glia 69: 1393\u20131412, https:\/\/doi.org\/10.1002\/glia.23968.","DOI":"10.1002\/glia.23968"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_239","doi-asserted-by":"crossref","unstructured":"Wongprayoon, P. and Govitrapong, P. (2021). Melatonin receptor as a drug target for neuroprotection. Curr. Mol. Pharmacol. 14: 150\u2013164, https:\/\/doi.org\/10.2174\/18744672mta17otcb0.","DOI":"10.2174\/1874467213666200421160835"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_240","doi-asserted-by":"crossref","unstructured":"Xiao, L. and Loh, Y.P. (2022). Neurotrophic factor-\u03b11\/carboxypeptidase E functions in neuroprotection and alleviates depression. Front Mol. Neurosci. 15: 918852, https:\/\/doi.org\/10.3389\/fnmol.2022.918852.","DOI":"10.3389\/fnmol.2022.918852"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_241","doi-asserted-by":"crossref","unstructured":"Xiao, L., Sharma, V.K., Toulabi, L., Yang, X., Lee, C., Abebe, D., Peltekian, A., Arnaoutova, I., Lou, H., and Loh, Y.P. (2021). Neurotrophic factor-\u03b11, a novel tropin is critical for the prevention of stress-induced hippocampal CA3 cell death and cognitive dysfunction in mice: comparison to BDNF. Transl. Psychiatry 11: 24, https:\/\/doi.org\/10.1038\/s41398-020-01112-w.","DOI":"10.1038\/s41398-020-01112-w"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_242","doi-asserted-by":"crossref","unstructured":"Xiao, L., Yang, X., Sharma, V.K., Abebe, D., and Loh, Y.P. (2023). Hippocampal delivery of neurotrophic factor-\u03b11\/carboxypeptidase E gene prevents neurodegeneration, amyloidosis, memory loss in Alzheimer\u2019s Disease male mice. Mol. Psychiatry 28: 3332\u20133342, https:\/\/doi.org\/10.1038\/s41380-023-02135-7.","DOI":"10.1038\/s41380-023-02135-7"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_243","doi-asserted-by":"crossref","unstructured":"Xing, Y.-q., Li, A., Yang, Y., Li, X.-x., Zhang, L.-n., and Guo, H.-c. (2018). The regulation of FOXO1 and its role in disease progression. Life Sci. 193: 124\u2013131, https:\/\/doi.org\/10.1016\/j.lfs.2017.11.030.","DOI":"10.1016\/j.lfs.2017.11.030"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_244","doi-asserted-by":"crossref","unstructured":"Yamamoto, K., Yoshida, H., Kokame, K., Kaufman, R.J., and Mori, K. (2004). Differential contributions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE and ERSE-II. J.\u00a0Biochem. 136: 343\u2013350, https:\/\/doi.org\/10.1093\/jb\/mvh122.","DOI":"10.1093\/jb\/mvh122"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_245","doi-asserted-by":"crossref","unstructured":"Yamamoto, M., Kiyota, T., Walsh, S.M., Liu, J., Kipnis, J., and Ikezu, T. (2008). Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J.\u00a0Immunol. 181: 3877\u20133886, https:\/\/doi.org\/10.4049\/jimmunol.181.6.3877.","DOI":"10.4049\/jimmunol.181.6.3877"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_246","doi-asserted-by":"crossref","unstructured":"Yang, Z., Kuboyama, T., and Tohda, C. (2019). Naringenin promotes microglial M2 polarization and A\u03b2 degradation enzyme expression. Phytother Res. 33: 1114\u20131121, https:\/\/doi.org\/10.1002\/ptr.6305.","DOI":"10.1002\/ptr.6305"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_247","doi-asserted-by":"crossref","unstructured":"Yang, Y., Bagyinszky, E., and An, S.S.A. (2023a). Presenilin-1 (PSEN1) mutations: clinical phenotypes beyond Alzheimer\u2019s disease. Int. J.\u00a0Mol. Sci. 24, https:\/\/doi.org\/10.3390\/ijms24098417.","DOI":"10.3390\/ijms24098417"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_248","doi-asserted-by":"crossref","unstructured":"Yang, Y., Seok, M.-J., Kim, Y.E., Choi, Y., Song, J.-J., Sulistio, Y.A., Kim, S.-h., Chang, M.-Y., Oh, S.-J., Nam, M.-H., et al.. (2023b). Adeno-associated virus (AAV) 9-mediated gene delivery of Nurr1 and Foxa2 ameliorates symptoms and pathologies of Alzheimer disease model mice by suppressing neuro-inflammation and glial pathology. Mol. Psychiatr. 28: 5359\u20135374, https:\/\/doi.org\/10.1038\/s41380-022-01693-6.","DOI":"10.1038\/s41380-022-01693-6"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_249","doi-asserted-by":"crossref","unstructured":"Yiannopoulou, K.G. and Papageorgiou, S.G. (2013). Current and future treatments for Alzheimer\u2019s disease. Ther. Adv. Neurol. Disord. 6: 19\u201333, https:\/\/doi.org\/10.1177\/1756285612461679.","DOI":"10.1177\/1756285612461679"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_250","doi-asserted-by":"crossref","unstructured":"Yiannopoulou, K.G. and Papageorgiou, S.G. (2020). Current and future treatments in alzheimer disease: an update. J.\u00a0Cent. Nerv. Syst. Dis. 12, https:\/\/doi.org\/10.1177\/1179573520907397.","DOI":"10.1177\/1179573520907397"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_251","doi-asserted-by":"crossref","unstructured":"Yu, Y. and Ye, R.D. (2015). Microglial A\u03b2 receptors in Alzheimer\u2019s disease. Cell Mol. Neurobiol. 35: 71\u201383, https:\/\/doi.org\/10.1007\/s10571-014-0101-6.","DOI":"10.1007\/s10571-014-0101-6"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_252","doi-asserted-by":"crossref","unstructured":"Yuan, X.Z., Sun, S., Tan, C.C., Yu, J.T., and Tan, L. (2017). The role of ADAM10 in Alzheimer\u2019s disease. J.\u00a0Alzheimers Dis. 58: 303\u2013322, https:\/\/doi.org\/10.3233\/jad-170061.","DOI":"10.3233\/JAD-170061"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_253","doi-asserted-by":"crossref","unstructured":"Zenaro, E., Piacentino, G., and Constantin, G. (2017). The blood-brain barrier in Alzheimer\u2019s disease. Neurobiol. Dis. 107: 41\u201356, https:\/\/doi.org\/10.1016\/j.nbd.2016.07.007.","DOI":"10.1016\/j.nbd.2016.07.007"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_254","doi-asserted-by":"crossref","unstructured":"Zhang, Y.W. and Xu, H. (2007). Molecular and cellular mechanisms for Alzheimer\u2019s disease: understanding APP metabolism. Curr. Mol. Med. 7: 687\u2013696, https:\/\/doi.org\/10.2174\/156652407782564462.","DOI":"10.2174\/156652407782564462"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_255","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Chen, H., Li, R., Sterling, K., and Song, W. (2023). Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct. Targeted Ther. 8: 248, https:\/\/doi.org\/10.1038\/s41392-023-01484-7.","DOI":"10.1038\/s41392-023-01484-7"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_256","doi-asserted-by":"crossref","unstructured":"Zhao, L., Gottesdiener, A.J., Parmar, M., Li, M., Kaminsky, S.M., Chiuchiolo, M.J., Sondhi, D., Sullivan, P.M., Holtzman, D.M., Crystal, R.G., et al.. (2016). Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models. Neurobiol. Aging 44: 159\u2013172, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.04.020.","DOI":"10.1016\/j.neurobiolaging.2016.04.020"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_257","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Wu, X., Li, X., Jiang, L.L., Gui, X., Liu, Y., Sun, Y., Zhu, B., Pi\u00f1a-Crespo, J.C., Zhang, M., et al.. (2018). TREM2 is a receptor for \u03b2-amyloid that mediates microglial function. Neuron 97: 1023\u20131031.e1027, https:\/\/doi.org\/10.1016\/j.neuron.2018.01.031.","DOI":"10.1016\/j.neuron.2018.01.031"},{"key":"2026022416431476121_j_revneuro-2025-0025_ref_258","doi-asserted-by":"crossref","unstructured":"Zhao, N., Ren, Y., Yamazaki, Y., Qiao, W., Li, F., Felton, L.M., Mahmoudiandehkordi, S., Kueider-Paisley, A., Sonoustoun, B., Arnold, M., et al.. (2020). Alzheimer\u2019s risk factors age, APOE genotype, and sex drive distinct molecular pathways. Neuron 106: 727\u2013742.e726, https:\/\/doi.org\/10.1016\/j.neuron.2020.02.034.","DOI":"10.1016\/j.neuron.2020.02.034"}],"container-title":["Reviews in the Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2025-0025\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2025-0025\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:44:07Z","timestamp":1771951447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2025-0025\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":256,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,12,17]]}},"alternative-id":["10.1515\/revneuro-2025-0025"],"URL":"https:\/\/doi.org\/10.1515\/revneuro-2025-0025","relation":{},"ISSN":["0334-1763","2191-0200"],"issn-type":[{"value":"0334-1763","type":"print"},{"value":"2191-0200","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}